Construction
Pennsylvania’s Construction Statute of Repose Under Attack
For more than 40 years, Pennsylvania’s Construction Statute of Repose (SOR) has given contractors, engineers, and architects the assurance that liability for completed projects eventually comes to an end. That is because, after 12 years from substantial completion, all claims are barred, no matter when the alleged defect is discovered. That certainty, however, is under direct attack in Pennsylvania. Currently, two cases are pending before the Pennsylvania Supreme Court seeking to expand liability in ways that undermine the statute’s purpose and create indefinite exposure for architects, engineers, and construction contractors. In our role as A/E/C industry advocates, Offit Kurman was engaged by leading construction industry associations to file friends of the court briefs (amicus briefs) in both appeals to Pennsylvania’s highest court. Offit Kurman Advocates for AEC Groups in Key PA Construction Case Nine AEC Professional Associations Advocate in Pennsylvania Supreme Court Case What is the Construction Statute of Repose? A statute of repose, by definition, sets a definitive event for the statutory period to begin and then provides for an expiration period that is not tolled. The statute of repose differs fundamentally from a statute of limitations because repose can operate to bar a lawsuit before a cause of action accrues. By contrast, a statute of limitations runs from the time of injury or reasonable discovery of harm. For more than 40 years, the Pennsylvania Construction Statute of Repose has created a hard cutoff point for lawsuits brought against architects, engineers, and contractors who furnish design, planning, and construction services for any improvement to real property. Generally, this requires any such suit to be brought within 12 years of substantial completion. Once the repose period expires, all claims are barred, even if the defect was hidden or the injury occurred later. There are various policy considerations for the adoption of a construction statute of repose. First, unlike most products and services, architectural, engineering, and construction services that improve real property are intended to long outlive the owner. Because the intent is for buildings and infrastructure projects to have long life spans, which include renovation and rehabilitation, state legislatures have typically limited the time period during which construction professionals can be held liable for alleged design and construction defects. The reality is that there is a practical balance: involving years elapsing, records being lost, memories fading, and the individuals who were involved on the projects being unavailable, as a result of retirement or death, that makes defending against stale claims exceptionally difficult. By creating a clear endpoint, construction statutes of response protect the A/E/C industry while also ensuring predictable costs for owners and the public. State legislatures within 48 of the United States have adopted a construction statute of repose. Pennsylvania’s 12-year statute of repose ranks as one of the two longest statutes of repose in the country. Aloia v. Diament – The Meaning of “Lawfully Performing” The first challenge seeks to nullify the construction statute of repose arguing that the statutory provision which states that a person “lawfully performing” means that if a plaintiff alleges any violation of a regulation or building code the statutory period does not start to run. In Aloia v. Diament, a homeowner argues that because the construction of the home’s exterior envelope allegedly violated building codes, the contractor was not “lawfully performing” the construction work. On that basis, the plaintiffs contend the 12-year repose period never began to run, leaving the claims alive decades later. Offit Kurman’s amicus brief, filed on behalf of leading national and state design professional associations, including the American Institute of Architects and American Council of Engineering Companies, makes clear that plaintiffs’ argument completely erases Pennsylvania’s construction statute of repose by not paying attention to the plain and unambiguous text and purpose. Nearly every design and construction defect claim involves alleged code and regulatory violations; if “lawfully performing” meant “perfect,” the repose period would never commence to run. Instead, “lawfully performing or furnishing” design or construction services clearly means authorized, meaning that the design professional or contractor was licensed or otherwise permitted to perform the work. This interpretation aligns with Black’s Law Dictionary (“authorized or sanctioned by law”) and with the legislative purpose of the statute of repose. In other words, “lawfully performing” modifies the qualifications of the architect or engineer, not whether every detail of the design complies with every regulatory or code provision. Clearfield County v. Transystems – Public Projects and Nullum Tempus The second case on appeal to the Pennsylvania Supreme Court arises from renovations to the Clearfield County Jail. The original construction of the Clearfield County Jail was substantially completed in 1981. In 2021, more than 40 years after its substantial completion, the county alleged design and construction defects in the original design and construction seeking to avoid the construction statute of repose by invoking nullum tempus occurrit regi—the ancient common law doctrine that “time does not run against the king.” The county argues that nullum tempus exempts it from the 12-year bar. Offit Kurman was asked by nine design professional and construction associations, including ACEC-PA and all Pennsylvania Chapters of the Associated Builders and Contractors, to prepare an amicus brief in opposition to the county’s position. The amicus brief emphasizes three main points: Statutory Finality – The construction statute of repose eliminates causes of action after 12 years, thereby legislatively abrogating the common law doctrine of nullum tempus. Sovereign Immunity Limits – Nullum tempus is a privilege of the Commonwealth itself, not counties or municipalities. Voluntary Contracting – Even if nullum tempus applied more broadly to a statute of repose, it cannot shield a governmental entity voluntarily entering into design and construction contracts to improve real property. If accepted, Clearfield’s argument would mean every public project remains open to claims indefinitely, driving up insurance premiums, discouraging bidders, and ultimately increasing costs for public improvements for the taxpayers of the Commonwealth. Proposed Legislative Reforms to the Statute of Repose Because of the importance of the statute of repose, Offit Kurman has provided legal advice to associations within the A/E/C industry on legal reforms to bring the 12-year statute of repose in line with statutes adopted by other states, so that Pennsylvania is not at a competitive disadvantage. In addition, the legislative coalition of A/E/C trade associations is seeking to address the potential negative outcome of either of the Supreme Court appeals. Senate Bill 399 is currently referred to the Senate Judiciary Committee and would shorten Pennsylvania’s statute of repose from 12 years to six, bringing it closer to the national norm. Why It Matters If either appeal reverses the findings of the trial courts or if legislative reforms are not adopted, the impact on Pennsylvania’s construction economy will be profound. The potential ramifications include: Indefinite Liability – Design professionals and contractors would face claims long after projects reach substantial completion, even into retirement or estate administration. Insurance Burdens – Design Professionals and contractors would be required to carry liability insurance indefinitely, even when such coverage almost certainly is not available. Increased Costs – Design Professionals and contractors will build risk premiums into proposals and bids for public and private projects, passing costs directly to taxpayers and owners. The construction statute of repose was enacted in 1965 to prevent exactly these outcomes. Offit Kurman’s Construction Practice Group continues to work with A/E/C design and construction to protect the industry. Franklin C. Miller, Jr., Counsel at Offit Kurman, played a key role in supporting Anthony Potter with the preparation of the amicus brief. We also acknowledge the valuable contributions of Law Clerk Robyn St. Hilaire to this article.
September 5, 2025
Commercial Litigation
Shutting Down a Scam Lawsuit in Three Days
Imagine waking up to a bank notification that you just received money from a total stranger. That’s exactly what happened to a recent out-of-state client of mine. Eight months pregnant, no ties to Virginia, and without a clue as to who the mystery sender was. Suspecting an honest mistake, or at worst, fraud, she immediately contacted her bank and had the mysterious Zelle transaction reversed that same day. Problem solved, right? Not even close. From Push Notification to Pressure Campaign A few days after the reversal, my client began receiving text messages and phone calls from someone claiming to be the original sender. This individual insisted that she return the money, despite the bank having already reversed the transaction. The client calmly explained this and cut off contact. Then came the real twist. Weeks later, she was served with a Warrant in Debt in Virginia from someone she had never heard of. Panic set in. Not only was she facing a court hearing in a state where she didn’t reside, but she had less than a week to respond. That’s when she called me. Three Names, Zero Credibility When I reviewed the case, it quickly became clear: this wasn’t a legitimate debt collection, but rather a shakedown. The person who filed the lawsuit wasn’t the one who originally Zelle’d her the funds, nor was it the same individual who had been texting and calling her. In fact, three different names were tied to this single scam. Furthermore, the claim was riddled with procedural issues, including questionable service, jurisdictional overreach, and no coherent claim. It had all the hallmarks of a desperate (and sloppy) attempt to intimidate someone into paying money they didn’t owe. Courtroom Showdown — Or Not I appeared on her behalf at the hearing. When the would-be scammer saw I was there and prepared with a stack of papers, he looked stunned. Clearly, he didn’t expect anyone to show up, let alone with legal representation ready to pick apart the claim. I laid out the numerous procedural deficiencies and jurisdictional arguments. The plaintiff folded. The case was dismissed immediately. Why This Case Matters This case serves as a reminder of how scammers are evolving and how the legal system can be weaponized in new ways to harass and intimidate. It’s also a testament to how effective legal help can make a difference. With just a few days’ notice, we were able to respond, appear, and get the case thrown out. Allowing the client to put the ordeal behind her. If you’ve been blindsided by a suspicious lawsuit or served with something that just doesn’t feel right, trust your instincts and don’t wait. Getting a legal opinion early can be the difference between panic and peace of mind.
August 29, 2025
Bankruptcy
One Way or Another: Non-U.S. Crypto Customers Will Have to Face Celsius Preference Lawsuits
Why You Should Read Terms Before You Click or Check the Box with “I Agree” As Blondie sings: One way, or another, I'm gonna find ya I'm gonna get ya, get ya, get ya, get ya One way, or another, I'm gonna win ya I'm gonna get ya, get ya, get ya, get ya Earlier this summer, the Bankruptcy Court for the Southern District of New York rejected a challenge to the Litigation Administrator, Moshin Y. Meghji, lawsuits against Celsius Network LLC customers. The challenge was based on, among other grounds, lack of personal jurisdiction over defendants who resided outside of the United States and undertook transactions with Celsius online. The litigation administrator asked the Bankruptcy Court to hold that the foreign defendants were subject to personal jurisdiction, and that the preferential transfers they received were domestic transfers for the purposes of the preference avoidance provisions of the Bankruptcy Code, or, in the alternative, that these provisions of the Code applied extraterritorially. The foreign defendants argued that jurisdiction cannot be decided without a factual record, given questions about which entity owned the crypto, inconsistent Terms of Use provisions, potential fraudulent inducement, and the heavy burden on foreign defendants to litigate in the U.S. In his July 29 decision, Judge Glenn held that a bankruptcy court may exercise jurisdiction over a foreign defendant if the defendant has minimum contacts with the United States as a whole. The court further found that, as to all customers, the transfers were domestic and involved a domestic application of the Bankruptcy Code. Because the transfers are domestic in nature, the court did not reach the issue of extraterritoriality[1]. The court held that the transfers were domestic in nature because they were made from a Delaware company via LLC-designated frictional wallets and workspaces. The court’s analysis meticulously followed the textbook test for exercising specific personal jurisdiction over a non-resident defendant. Judge Glenn reviewed the three requirements that must be satisfied: “(i) a defendant must have purposefully availed itself of the privilege of conducting activities within the forum State or have purposefully directed its conduct into the forum State, or the United States when the issue arises in adversary proceedings in bankruptcy courts; (ii) the plaintiff’s claim arises out of or relates to the defendant’s forum conduct; and (iii) the exercise of jurisdiction must be “reasonable under the circumstances.” U.S. Bank Nat’l Ass’n v. Bank of Am. N.A., 916 F.3d 143, 150 (2d Cir. 2019).” Why the Court Found There was Personal Jurisdiction All non-US customers were bound by the Terms of Use, which contained a New York choice of law provision and a forum selection clause requiring litigation in New York courts, and that had shifted Celsius’ primary business operations, relationships, and obligations away from a U.K. entity to a U.S. company. Accordingly, the Bankruptcy Court found that the foreign defendants’ decision to contract with the U.S. company manifests an intent to purposefully direct their activities at the forum. Defendants have contracted to open accounts in a U.S.-based entity and signed a contract subject to the laws of the State of New York. The transfers were made by a U.S. entity to the foreign defendants accounts. “[A] contract with a New York choice of law provision is “a significant factor in a personal jurisdiction analysis because the parties . . . invoke the benefits and protections of New York law.” In re Celsius Customer Preference Actions, No. 24-04024 (MG), 2025 WL 2125270 (Bankr. S.D.N.Y. July 29, 2025) citing Sec. Inv. Prot. Corp. v. Bernard L. Madoff Inv. Sec., LLC, 460 B.R. 106, 117 (Bankr. S.D.N.Y. 2011), aff'd, 474 B.R. 76 (S.D.N.Y. 2012). These principles, Judge Glenn, emphasized also apply to clickwrap agreements. Id. at 12 citing Zaltz v. JDATE, 952 F. Supp. 2d 439, 451–55 (E.D.N.Y. 2013) (finding plaintiff assented to defendant’s terms of service when she clicked a box agreeing to the defendant's terms of service). Additional analysis of the forum selection clauses also supported the finding of personal jurisdiction over the foreign defendants. The Terms of Service included the following language: [t]he relationship between you and Celsius is governed exclusively by the laws of the state of New York. . . . Any dispute arising out of, or related to, your Celsius Account or relationship with Celsius must be brought exclusively in the competent courts located in New York, NY and the U.S. District Court located in the Borough of Manhattan. . . . Judge Glenn held that the Terms of Use were reasonably communicated to the defendants, the forum selection clause was mandatory, and the claims and parties involved in the litigation were subject to the forum selection clause. Lastly, the court held that the foreign defendants have not demonstrated a strong showing to rebut the presumption of enforceability. The court was not persuaded by the argument that an individualized determination with respect to each defendant was necessary, and the court could not rule on the defendants “en masse,” because the defendants did not dispute that the Terms of Use that were active during the preference period contained a forum selection clause. While allegations of fraudulent inducement and other defenses may be addressed in future proceedings, the court concluded that the litigation administrator had made a prima facie showing of personal jurisdiction over all defendants. In summary, Judge Glenn’s decision reinforces a clear message: engaging with U.S.-based platforms — even digitally —comes with legal obligations. The ruling not only affirms the reach of U.S. bankruptcy jurisdiction but also sets a precedent for how courts may treat cross-border crypto transactions going forward. The fine print matters! [1] As Judge Glenn pointed out the presumption against extraterritoriality is a “basic premise of our legal system.” It provides that “[a]bsent clearly expressed congressional intent to the contrary, federal laws will be construed to have only domestic application.” RJR Nabisco v. Eur. Cmty., 579 U.S. 325, 335 (2016) (citing Morrison v. Nat’l Australia Bank Ltd., 561 U.S. 247, 255 (2010)). The two-step inquiry, when analyzing extraterritoriality issues, requires to ascertain if a statute gives a clear indication of an extraterritorial application and if there is no such clear indication of an extraterritorial reach then a court has to examine the statute’s ‘focus’ to determine whether the case involves a domestic application of the statute.
August 27, 2025
Business
Non-Compliance with CMMC Could Put Your DoD Contracts at Risk
This past month, the Department of Defense sent the final rule for the new Cybersecurity Maturity Model Certification (CMMC) program under the Federal Acquisition Regulation to the Office of Information and Regulatory Affairs for review. This action precedes the inclusion of the new rule in Department of Defense contracts beginning this autumn. So, it is time to get into compliance for all who have been delaying the inevitable. Below is a quick review of these requirements. Background CMMC is designed to bolster the cybersecurity posture of the DoD’s supply chain by validating that DoD contractors and subcontractors possess the necessary cybersecurity practices and processes to safeguard Federal Contract Information (FCI) and various kinds of Controlled Unclassified Information (CUI). CMMC introduces a tiered, certification-based approach, ranging from Level 1 (basic cybersecurity practices for FCI) to Level 2 (advanced practices for most CUI), and Level 3 (expert practices for sensitive CUI). Why is This Important? Contractors and subcontractors must attain the appropriate CMMC level aligned with the security requirements of their contracts to bid and work on DoD projects. In addition to the cybersecurity and reputational risks of non-compliance, if contractors and subcontractors fib or cut corners, they could face False Claims Act (FCA) liability, including draconian damage and penalty assessments. One disgruntled employee who decides to bring an FCA complaint can cost a company significant pain. Contracts Covered by CMMC The CMMC requirement applies to DoD acquisitions that involve the handling of FCI and CUI. Major Contract Programs: Contracts for the procurement of defense systems, weapons, military equipment, and related services that require access to CUI or FCI will be directly impacted. This includes a broad spectrum of procurement categories across the DoD, from large-scale hardware contracts to software development and services. Subcontractors and Supply Chain: Importantly, the rule also extends to subcontractors at all tiers. This flow-down creates a ripple effect throughout the defense supply chain. Contracts Not Subject to CMMC While the rule is broad, it does not universally apply to all federal contracts. FAR Part 12 Commercial Item Contracts: Some commercial item contracts purchased under FAR Part 12 may be excluded unless the scope involves sensitive information or national security concerns. Contracts with No Access to CUI or FCI: Contracts that do not involve access to or handling of CUI/FCI will not be subject to CMMC requirements. Other Exceptions: The FAR Council has provisions for exemptions for technical or administrative reasons, but these are limited and require justification. What is FCI If you are a contractor or subcontractor that handles controlled information such as CUI, you likely have some sophistication regarding cybersecurity. But those with FCI may not be aware that they have protectible information, and most medium and larger-sized DoD contracts will have FCI. FCI refers to information that is not intended for public release but is provided by the federal government to a contractor or subcontractor for the purpose of fulfilling a federal contract. It includes data that is critical to the performance of government contracts. Examples include technical data (e.g., details about a supplier’s hardware specifications), contract schedules and milestones (e.g., timelines for delivering military equipment), and financial or administrative information shared with contractors. Typical Contracts:Smaller contracts Basic supply chain activities FCI Requires Level 1: Basic Cyber Hygiene Key Requirements: Implementation of basic controls, including access only by authorized users, maintaining identification and authentication, and physical protection of information systems. Practices include routine login credentials, portable device protections, and basic awareness training. Annual self-assessment and annual affirmation of compliance with CMMC requirements. What is CUI It’s not classified information, but it is information that requires safeguarding pursuant to various laws, regulations, and government policy. Examples include information about physical security, system vulnerability, or operational issues. CUI Requires Level 2 (Intermediate) or Level 3 (Expert) Processes Level 2: Intermediate Cyber HygienePractices: 110 practices, aligned with NIST SP 800-171 security requirements. Focus: Establishing more disciplined cybersecurity processes and practices suitable for organizations handling CUI. Third-party assessments are required for certification at this level. Level 3: Expert Cyber HygienePractices: Over 130 security controls, closely aligned with NIST SP 800-171, plus some additional practices. Focus: A mature, enterprise-wide cybersecurity program. This will apply only to a limited number of contractors with larger, more sensitive defense contracts that require higher levels of CUI protection. Third-party assessment is required.
August 27, 2025
Healthcare
Can You Take Patient Records When Leaving a Medical Practice?
No, you generally cannot take original patient records with you when leaving a medical practice. Patient records are considered the property of the practice or healthcare organization, not the individual physician. However, under HIPAA, you may request copies or access to relevant information for continuity of care, provided you follow proper legal and ethical procedures. This post will cover HIPAA rules on transferring or copying records when a provider leaves. It will also let you know best practices for maintaining continuity of care without violating HIPAA. Who Owns Patient Records? Ownership of patient records is a complex issue that depends on the laws of the jurisdiction, as well as the agreements between healthcare providers and their organizations. In the United States, the general rule is that the medical practice or healthcare facility owns the physical or electronic patient records, not the individual physician. Even if a physician has treated a patient for years, the records typically remain the property of the practice, hospital, or clinic where the care was delivered. Patients, however, do not “own” the records themselves, but they do have a legal right to access and obtain copies of their health information. Under HIPAA (Health Insurance Portability and Accountability Act) in the U.S., patients must be granted access to their records upon request, within specific timelines. HIPAA is primarily concerned with protecting the privacy and security of protected health information (PHI), rather than dictating record ownership. Outside the U.S., different laws apply. For instance, in the European Union, the GDPR (General Data Protection Regulation) governs how patient data is collected, stored, and used. While healthcare providers still maintain control over the records, GDPR emphasizes the patient’s rights to access, correct, and request deletion of their personal health data in certain circumstances. Similarly, many countries have their own healthcare privacy and data protection regulations that define ownership, access rights, and provider responsibilities. Am I Legally Allowed to Take Records When Leaving a Practice? When a physician is departing a medical practice, one of the most common questions is whether they can take patient records with them. In nearly all circumstances, patient medical records belong to the medical practice or healthcare entity, not the individual physician. This principle applies whether records are maintained in electronic or paper form. While a departing physician may be able to obtain copies under certain conditions, they cannot remove or transfer such medical records without following strict state and federal laws. The Health Insurance Portability and Accountability Act (HIPAA) is the key federal law governing the confidentiality and transfer of health information. It requires that health care providers and covered entities maintain control over the designated record set and protect medical record confidentiality. In addition to HIPAA, state law often governs how records are retained, how patients are notified, and the time frame for medical record retention. Violating these rules can result in disciplinary action, fines, or loss of a medical license. Physicians and staff cannot generally take copies of patient records for their own personal reference or to use in a new practice. Any access to healthcare provider records must serve a legitimate purpose, such as continuing care or compliance with legal obligations. If a departing physician needs to access patient information, they must comply with both state and federal requirements, as well as any restrictions in their employment contract or group practice agreement. There are limited circumstances where a physician may be allowed to obtain copies of records, but such access is often on a case-by-case basis and requires patient consent or authorization. Even then, the healthcare provider must ensure that proper documentation is maintained to demonstrate compliance with the HIPAA Privacy Rule and applicable state law. Taking patients’ medical records without permission can lead to severe consequences. It can result in civil penalties, loss of the right to practice medicine, and reputational harm for both the individual and the physician practice. In addition, the federal government and state regulatory agencies may impose fines for improper handling of health information technology or electronic formats of records. Most employment contracts and practice agreements also have clauses addressing ownership and handling of records. Violating these terms could lead to lawsuits, loss of privileges within a physician group, and other legal obligations. A departing physician must be extremely cautious to avoid jeopardizing their career when transitioning to a new provider or new practice. What Does HIPAA or State Law Say About Patient Record Transfers? Under HIPAA, patient records must remain with the original covered entity or healthcare provider, but patients themselves have the right to request easy access to their information within a reasonable period. Patients may request that their records be transferred to a new provider for continuing care, and the original practice is obligated to comply within the set period defined by law. State and federal laws may vary on how records are handled, especially regarding medical record retention. For example, most states require that records be retained for a certain number of years, even if the physician is no longer practicing at that location. Some states require the practice to notify patients and provide a forwarding address if a physician leaves, ensuring patients can still request copies and maintain access to their health information. Can You Make Copies of Patient Records for Personal Use? Making copies of patient records for purely personal use is not permitted. A physician cannot simply download or photocopy records for their files, regardless of whether those records are in paper form or electronic formats. The difference between records for personal use and official practice records is crucial. Only the latter are recognized as legally valid and must remain with the practice or hospital that maintains them. Copies may be made if the patient or their personal representative signs a proper authorization, allowing their information to be shared with a new practice or new provider. In such circumstances, the physician must document consent and maintain proof of authorization in compliance with the HIPAA Privacy Rule and any other law that applies. This ensures that both the patient’s right to access is honored and that the healthcare provider remains in full compliance with the Portability and Accountability Act and relevant state law. What Are Your Ethical Duties With Patient Records? Physicians and healthcare providers have a fundamental ethical duty to maintain patient confidentiality at all times. This obligation extends beyond the requirements of state and federal laws like HIPAA and reflects the trust patients place in their providers. Whether records are kept in electronic or paper form, safeguarding the privacy of health information is central to the physician–patient relationship. Another key duty is ensuring continuity of care when a physician leaves a medical practice or joins a new provider. Patients must not be left without access to their records or a way to continue treatment. This means that records should be transferred in compliance with the HIPAA Privacy Rule, with proper authorization and within the legally mandated period, so that patient care is not disrupted. Physicians must also avoid conflicts of interest or any misuse of patient medical records. Records cannot be taken for competitive purposes, used for marketing, or retained for personal gain. Instead, they must be managed with integrity, respecting medical record confidentiality and the patient’s rights. At all times, the physician has an ethical obligation to act in the patient’s best interest when handling such medical records. This includes providing access when requested, cooperating with personal representatives, and respecting the patient’s autonomy over their health information. Finally, ethical practice requires strict adherence to professional guidelines on record management. Organizations such as the American Medical Association (AMA) and specialty boards emphasize that physicians must comply with legal obligations while upholding professional standards. This means following proper procedures for medical record retention, transfer, and patient notification, ensuring compliance not only with the portability and accountability act but also with the broader principles of medical ethics. How Can You Transition Patient Medical Records Safely? When a physician leaves a medical practice, one of the most important responsibilities is ensuring that patients’ medical records are transferred safely and in compliance with both state and federal laws. This process must protect medical record confidentiality, honor patient rights, and ensure continuity of care. By taking the proper steps, a departing physician can transition patients’ records smoothly without risking HIPAA violations or patient trust. Here’s what to do: Notify the Practice and Patients: The first step is to inform your current employer and patients about your departure. Practices are often required to provide notice to active patients, along with instructions on how they can access or transfer their records. Transparency helps patients feel secure that their care will continue uninterrupted. Obtain Written Consent: Patients must provide written authorization before their patient records can be transferred to a new provider. This ensures compliance with the HIPAA Privacy Rule, which requires proper documentation before any health information can be shared. Secure the Records: Whether in electronic or paper form, all health information technology transfers must be handled with strict security. Encrypted digital transfers and locked physical methods help prevent breaches and maintain accountability under the Health Insurance Portability and Accountability Act. Create a Record Inventory: A complete inventory of the records being transferred should be prepared. This log ensures that no files are lost in the process and demonstrates compliance with both federal laws and state requirements for medical record retention. Coordinate with Receiving Provider: Communication with the new practice or receiving provider is essential. Physicians must confirm that the receiving office has secure systems in place to accept and store the records in accordance with applicable laws. Retain Copies if Allowed: In some circumstances, physicians may retain copies of certain healthcare provider records, but only if explicitly permitted by law or their employment contract. This is typically limited to supporting continuing care or meeting other legal obligations. Document the Process: Every step of the transfer, from patient notifications and consents to the actual transfer actions, should be documented. This documentation protects both the physician’s practice and the departing physician against future disputes. Follow State and Federal Regulations: Finally, compliance with the Portability and Accountability Act and relevant state and federal laws is non-negotiable. Each jurisdiction may impose different timelines and requirements, so it is crucial to follow both HIPAA and any local regulations to ensure a legally sound transfer. What Are the Legal Risks of Taking Patient Records? One major risk is being accused of theft or misappropriation of records. Even if the intention is to continue caring for active patients in a new practice, the unauthorized removal of records violates medical record confidentiality and can result in disciplinary action. A physician who takes records without authorization may also be charged with breaching federal laws such as the Health Insurance Portability and Accountability Act (also referred to as the Portability and Accountability Act). HIPAA requires that covered entities and health care providers maintain a designated record set securely, whether in electronic or paper form, and protect all health information. Another risk involves penalties for HIPAA Privacy Rule violations. Improper handling of records in electronic formats, paper form, or any other method can result in large fines from the federal government, along with potential restrictions on the ability to continue practicing medicine. In addition, state law may impose stricter rules regarding medical record retention and patient access. Failing to notify patients and provide a forwarding address when leaving a practice may result in further liability. Civil lawsuits are another potential consequence. Patients have the right to request copies of their records and expect easy access within a reasonable period. If a physician removes records without consent, patients may sue for damages arising from lack of access, interruption of treatment, or breach of privacy. Similarly, if an employment contract or group practice agreement violates contractual obligations, the original physician group or hospital may file claims. How Healthcare Lawyers Can Help You Avoid Legal Issues Given the complex intersection of state and federal requirements, any departing physician needs to consult a qualified healthcare attorney before attempting to move patient medical records. A lawyer can review the specific rules that apply in your jurisdiction, explain how the Accountability Act and other laws apply, and ensure compliance with both HIPAA and state law for retaining records. Legal advice is also critical to protect against HIPAA Privacy Rule violations or disputes with a former physician’s practice. For example, an attorney can advise whether it is legally permissible to obtain copies for continuing care, how to obtain authorization from a personal representative, or how to document patient consent when transferring records to a new practice or provider. Lawyers also help explain when certain rules apply, like situations where state or federal laws create two types of records: those that must stay with the practice and those that can be shared if the patient agrees. By consulting with experienced healthcare counsel, such as our team at Cohen Healthcare Law Group, physicians and healthcare providers gain confidence that they will comply with all applicable rules, avoid conflicts with patients or former employers, and transition into their new practice without unnecessary risk. With over 25 years of experience, Cohen Healthcare Law Group helps physicians navigate issues of medical record confidentiality, retention, and lawful patient transfers, ensuring they can continue to provide high-quality patient care while honoring their legal obligations. Need Help With Patient Records? Consult a Healthcare Lawyer When leaving a medical practice, ensuring that patient records are managed properly is both a legal and ethical responsibility. Physicians, staff, and patients all have rights and obligations under state and federal laws, including the Health Insurance Portability and Accountability Act (HIPAA). In summary, records belong to the practice, and patients have the right to request copies and easy access to their information, and providers must comply with strict rules regarding medical record confidentiality and medical record retention. Mishandling such medical records, whether in electronic or paper form, can result in serious legal risks for a departing physician or any healthcare provider. To transition safely, it is essential to follow the HIPAA Privacy Rule, honor patient consent requirements, and consult a knowledgeable healthcare attorney. FAQ Below are some answers based on state and federal laws, the HIPAA Privacy Rule, and professional standards of medical record confidentiality: What Happens to Patients’ Files When a Practice Is Closing? When a practice closes, the physicians must arrange for secure retention of medical records and notify patients about how to obtain copies or transfer their records to a new provider. Laws vary by state, but records are typically kept for a set period defined by federal laws and state law. Can a Doctor Take Patient Records When Leaving a Practice? A doctor cannot take original patient medical records when leaving a medical practice, since those records belong to the practice or facility. They may only obtain copies under certain conditions with proper patient consent and legal authorization. Do Patients Have the Right to Copies of Their Records? Yes, under HIPAA and most state laws, patients have the right to request copies of their medical records in either electronic or paper form within a reasonable period. Practices must provide access but may charge a small administrative fee. What Happens if Records Are Taken Without Permission? Taking such medical records without authorization can lead to accusations of theft, HIPAA violations, civil lawsuits, and disciplinary action against the healthcare provider. It also breaches both federal laws and professional ethical duties regarding medical record confidentiality. How Long Does the Process of Taking Patient Records When Leaving a Medical Practice Usually Take? Transferring patient records to a new practice usually takes a few days to several weeks, depending on the number of records, format, and state and federal requirements. HIPAA requires easy access within a specific timeframe, typically 30 days. What Costs Are Involved in Transferring Patient Records When Leaving a Medical Practice? Costs vary by state, but health care providers may charge reasonable fees for copying, mailing, or preparing electronic formats of health information. These costs are usually passed to the patient requesting the transfer, not the departing physician.
August 26, 2025
Labor and Employment
Evolving Standards for Religious Accommodations at Work
The legal framework surrounding religious accommodations in the workplace has evolved significantly, driven by recent court decisions, EEOC enforcement actions, and federal guidance. Employers must gain a clear understanding of these changes, to ensure compliance with Title VII of the Civil Rights Act of 1964. With heightened scrutiny on religious exemption requests, particularly in the wake of COVID-19 vaccine mandates, employers must stay informed to avoid costly litigation and foster inclusive workplaces. Key Court Rulings Clarify Religious Accommodation Standards Recent judicial decisions have reshaped how employers must evaluate religious accommodation requests under Title VII. Below are pivotal cases that highlight the courts’ focus on sincerity of belief and the elevated standard for denying accommodations. Second Circuit: Defining Sincerely Held Beliefs In Gardner-Alfred v. Federal Reserve Bank of New York, 143 F.4th 51 (2d Cir. 2025), the Second Circuit offered critical guidance on assessing “sincerely held” religious beliefs in the context of COVID-19 vaccine mandate exemptions. The Federal Reserve Bank of New York (FRBNY) terminated two employees after denying their religious exemption requests. The court’s ruling clarified: Low Threshold for Sincerity: Plaintiff Gardner-Alfred’s exemption request was dismissed due to its reliance on a generic “exemption package” lacking ties to specific religious practices. Employers can expect courts to require detailed, individualized expressions of belief. Inconsistency Does Not Disqualify: Co-plaintiff Diaz’s claim was revived despite inconsistent behavior (e.g., using medications potentially conflicting with her religious objections). The court emphasized that imperfect adherence does not negate sincerity. Misunderstandings Are Valid: Diaz’s objection to mRNA vaccines, based on a mistaken belief about fetal cell lines, was deemed genuine. Employers cannot dismiss requests due to factual inaccuracies. Other Landmark Cases Groff v. DeJoy, 143 S. Ct. 2279 (2023): The Supreme Court raised the bar for denying accommodations, requiring employers to show a “substantial increased cost” or operational burden. This decision significantly strengthens employee protections. Keene v. City and County of San Francisco, No. 22-16567 (9th Cir. 2024): The Ninth Circuit ruled that blanket denials of religious exemptions, without engaging in the interactive process, violate Title VII. Bube v. Aspirus Hospital, Inc., No. 22-cv-745 (W.D. Wis. 2024): A federal district court rejected a hospital’s denial of exemptions based on vague claims of workplace disruption, reinforcing the need for specific evidence of undue hardship. Employers must conduct individualized, respectful inquiries into the sincerity of religious beliefs and avoid denials based on assumptions or skepticism. EEOC’s Robust Enforcement of Religious Rights The Equal Employment Opportunity Commission (EEOC) has intensified its focus on religious accommodations, particularly in response to COVID-19 vaccine mandate disputes. Key developments include: Recent EEOC Appellate Decisions (August 4, 2025) The EEOC’s Office of Federal Operations issued three decisions clarifying accommodation standards: Department of Veterans Affairs: A physician requesting Friday afternoons off for prayer was offered reduced hours or an overly burdensome schedule. The EEOC ruled these options unreasonable, noting that accommodations causing employee disadvantage (e.g., reduced pay) are insufficient. Claims of “low morale” among staff were also deemed inadequate justification. Federal Reserve Board: A law enforcement officer’s exemption request was denied without exploring accommodations or documenting hardship. The EEOC applied the Groff standard retroactively, emphasizing the need for a thorough process. EEOC’s Enforcement Milestones (August 18, 2025) In its “200 Days of EEOC Action to Protect Religious Freedom at Work” press release, the EEOC reported: Over 10,000 charges related to religious accommodations for COVID-19 vaccine mandates More than $55 million recovered for workers, including a $1 million settlement with Mercyhealth Lawsuits against organizations like Silver Cross Hospital and the Mayo Clinic for improper denials of religious exemptions The EEOC is prioritizing robust enforcement, and employers face significant risks for cursory or unsubstantiated denials of religious accommodations. Federal Guidance Promotes Accommodation The Office of Personnel Management (OPM) issued memoranda on July 16 and July 28, 2025, urging federal agencies to adopt a pro-accommodation stance. Key points include: Emphasizing a good-faith interactive process with detailed documentation Encouraging low-cost solutions like telework or flexible scheduling, which require strong justification if denied While directed at federal agencies, these guidelines reflect broader expectations for all employers under Title VII. Practical Steps for Employers To navigate this high-scrutiny environment, employers should adopt the following strategies. Risk Area Actionable Steps Sincerity Challenges Conduct respectful interviews, focusing on the employee’s stated beliefs. Avoid demanding theological proof or overly intrusive inquiries. Undue Hardship Claims Provide specific, data-backed evidence of substantial costs or operational burdens. General claims like “staff discomfort” are insufficient. Manager Training Train supervisors on clear protocols for handling accommodation requests compassionately and escalating them appropriately. Policy Review Update accommodation policies to align with the Groff standard and EEOC’s enforcement priorities. Ensure procedures are transparent and consistent. Documentation Log every step of the interactive process to demonstrate compliance and build a defensible record. The Lasting Impact of COVID-Era Policies The legal and regulatory focus on religious accommodations, spurred by COVID-19 vaccine mandates, has created a lasting shift in employment law. From scheduling adjustments to exemption requests, religious considerations are now central to workplace compliance. Employers must stay proactive, ensuring policies and practices reflect the latest legal standards to avoid litigation and promote a respectful, inclusive workplace.
August 25, 2025
Estates and Trusts
Trust Protectors – Should You Have One?
When creating a trust, determining who you want to serve as trustee(s) and benefit from the trust as beneficiaries are decisions that need to be made for every trust. The role of “trust protector” may not be as commonly known or understood, but the decisions whether to have one and, if so, who might best serve in the role, can be key to a smooth administration. A “trust protector” can provide valuable trustee oversight, flexibility, and inexpensive revisability — especially in long-term or complex trust arrangements. Deciding whether to have one and, if so, who might best serve in the role, can be key to a smooth trust administration. What is a Trust Protector? A “trust protector” is a person or entity appointed to monitor and, if necessary, intervene in the administration of a trust. Unlike a trustee, the trust protector does not manage trust assets or distributions. Instead, they are granted specific powers, defined in the trust document, to ensure the trust continues to operate in line with the grantor’s intent. Typical powers of a trust protector may include some combination of the following: Removing or replacing a trustee Amending trust provisions to comply with changes in law Resolving disputes between trustees and beneficiaries Approving or vetoing certain trustee actions This role is especially useful in irrevocable trusts, where flexibility is generally pretty limited. Does My Trust Need a Trust Protector? Not every trust requires a trust protector, but there are several scenarios where appointing one may make more sense: Long-Term Trusts: Trusts designed to last decades or generations benefit from a mechanism to adapt to changing laws and circumstances. Irrevocable Trusts: Since these trusts are difficult to modify, a trust protector can provide limited flexibility without court involvement. Complex Family or Business Dynamics: If there’s potential for conflict or concern about trustee performance, a trust protector can serve as a neutral safeguard. Asset Protection or Offshore Trusts: These often include a trust protector as a standard feature to enhance oversight and control. How Do I Choose the Right Trust Protector? If you’ve chosen to include a trust protector, how do you how do you decide which person is the right fit for your particular trust? Electing the appropriate trust protector is critical to ensuring the role adds value rather than complexity, and every situation should be evaluated on its own merits. That said, you might want to consider some or all of the following when making your choice: Independence: Ideally, the trust protector should not be either a beneficiary or a trustee to minimize or avoid altogether potential conflicts of interest. Expertise: Legal, financial, or fiduciary experience is beneficial, especially if the trust is complex or long-term. Trustworthiness: As the name implies, this role requires someone who can be relied upon to act in good faith and consistently with and in furtherance of the grantor’s intent. Availability: The trust protector should be willing and able to serve for the duration of the trust or have a succession plan in place. Often, clients choose a trusted advisor, attorney, or corporate fiduciary to serve in this role. Common Misconceptions About Trust Protectors Despite their growing use, the purpose and/or responsibilities of trust protectors can be misunderstood. Here are a few common misconceptions: “Trust protectors replace trustees.” It depends on what is meant by “replace” in this context. They generally oversee and intervene with the authority to replace one or more trustees with another only when necessary (such as when a trustee is perceived to be abusing his or her position or failing to carry out the terms or intentions of the trust). Trust protectors do not, however, manage assets or make routine decisions by substituting or “replacing” their own judgment for that of the appointed trustee(s). “Only large or offshore trusts need a trust protector.” While the use of trust protectors is common for large or offshore trusts, trust protectors can be helpful in domestic estate plans, especially where flexibility or oversight is desired. Reasons why a particular trustee may have been named at the time of drafting may no longer apply when the time comes. Successor trustees may not be in a position to step in as established in the trust (due to age or health issues, for instance). With a trust protector in place, it can be like having an added layer of defense against life’s unexpected twists. “Appointing a trust protector complicates the trust.” If “complicates” means the addition of more words, then yes, the addition of a trust protector does complicate things. Nevertheless, when properly drafted, a trust with a built-in protector can simplify administration of the trust and reduce, or even eliminate altogether, the need for court involvement. Take the situation faced by Jimmy Buffett’s widow. With Jimmy’s former legal counselor/advisor and his wife on equal footing as trustees, they quickly deadlocked over what can, should, or must be done with the assets and distributions. A well-chosen trust protector in Jimmy Buffett’s case could have served as the needed tie-breaking vote and/or insisted upon a “change in attitude” or occasioned a “change in latitude” by ousting whichever of the trustees, in the judgment of the trust protector, seemed to be missing the settlor’s intention, or as Jimmy might have said, acting as the “people our parents warned us about.” Final Thoughts A trust protector is not an essential requirement but, in the right circumstances, can be a valuable addition to a trust. The presence of a trust protector can serve as a “check and balance” feature to help ensure your trust remains effective, adaptable, and aligned with your goals over time by providing oversight after you passed on. If you're wondering whether a trust protector is right for a new trust you are considering, simply be sure to mention it to your estate planner/drafting attorney. If considering revising an existing trust to add a trust protector, seek a second opinion, separate from the initial drafting attorney, to evaluate your specific needs and objectives and whether these are more likely to be met with or without a trust protector.
August 25, 2025
Healthcare
What Are the OTC Drug Label Requirements?
Over-the-counter (OTC) drugs are medications available without a prescription, intended to treat common health issues such as headaches, allergies, cold symptoms, or digestive discomfort. Under FDA regulations, OTC drug labels must follow a standardized drug facts format that includes active ingredients, purposes, directions, and more. In this article, we’re going to break down the importance of proper labeling for OTC drugs and walk you through the FDA’s specific OTC drug label requirements. What Are OTC Drug Label Requirements? OTC drug label requirements refer to the specific format and content standards that all over-the-counter (OTC) drug products must follow before being marketed to the public. These requirements ensure that the immediate container label, outer packaging, and any accompanying information provide consumers with clear, accurate, and complete details about the drug product’s purpose, uses, dosage, warnings, and ingredients. The applicable OTC drug monograph for each nonprescription drug product sets out what information must appear and in what form. In the United States, the primary regulatory body responsible for overseeing OTC drug regulations is the U.S. Food and Drug Administration (FDA). The FDA enforces labeling provisions under the Federal Food, Drug, and Cosmetic Act (FD&C Act), which apply to all nonprescription drug products, topical drug products, and other OTC medicines. Proper labeling is crucial for consumer safety because it communicates dosage warnings, separate allergy warnings, stomach bleeding warnings, sore throat warnings, and liver warnings, as well as other health risks that could necessitate immediate discontinuation of the drug. It is also essential for legal compliance, since products that do not meet OTC labeling format and content requirements may be considered misbranded and subject to enforcement action. In summary, OTC drug labels must follow strict FDA rules on format, ingredients, warnings, and claims. A healthcare lawyer helps ensure compliance, advises on whether your product fits under an FDA monograph or needs special approval, and reviews marketing to avoid FTC violations. If the FDA challenges your labeling or advertising, a lawyer like those at Cohen Healthcare Law can guide your response, reduce risk, and keep your product legally on the market. FDA Regulations on OTC Drug Labeling The FDA uses the OTC drug monograph system to establish standardized requirements for drug product labeling without needing an approved drug application. Each relevant OTC drug monograph details the active ingredient, labeling requirements, proper dosage, and necessary warnings, including specific alerts such as warnings for asthma or for pregnant users based on their trimester. The FDA requires a mandatory drug facts labeling format for all OTC medicines. This includes distinct headings, horizontal barlines, and consistent horizontal line spacing between sections. Certain warnings, such as a liver warning or asthma alert warning, must appear in a box and in red letters to ensure visibility. Labeling must also follow the standardized format and content requirements, which include how the drug facts labeling appears on the package, the subsequent panel immediately following the first, and the proper placement of additional bulleted statements appearing under the appropriate heading. Under the FD&C Act, drug product labeling must also meet packaging techniques intended to protect the drug from undergoing chemical change and to ensure that the dosage unit stated remains accurate. The FDA distinguishes between OTC and prescription drug labeling requirements. Prescription drug labels are tailored for healthcare professionals, whereas OTC medicine labels are designed for direct consumer use with complete instructions for safe self-administration. What Information Is Required on an OTC Drug Label? One of the requirements of an OTC drug label is the drug facts panel. This panel should include: Active ingredients—The common or usual name and the appropriate dosage unit for each. Purpose of the drug—The principal intended actions, such as pain relief, cough suppression, or fever reduction. Uses—Conditions or symptoms the drug product is marketed to treat. Warnings—This includes allergy alerts, separate allergy warnings, stomach bleeding warnings, sore throat warnings, dosage warnings, and any statement that would necessitate immediate discontinuation of the product. Special provisions may include an asthma alert warning set or a complete additional bulleted statement for conditions like liver damage risk. Directions for use—The dosage directions for each age group should be stated in discrete dosage units and in the same line as other dosing instructions. Other information – Storage instructions, inactive ingredients, and any toll-free number to report complaints. There should also be a product identity, which must be clear on the principal display panel. It should include the name of the drug, the net quantity of contents, and any statement required by the applicable OTC drug monograph or proposed labeling provisions. Additionally, there should be the manufacturer’s information. This must list the name and address of the manufacturer, packer, or distributor, either on the principal display panel or on such an exterior container as the immediate container label. Can OTC Drug Label Requirements Vary by Country? Yes, OTC drug regulations and labeling provisions vary significantly across countries. While the U.S. FDA has strict rules for how drug facts should be labeled, other countries might have different requirements, like needing extra warnings about sexually transmitted diseases or disclaimers for spermicide products. Some regions may require the same line formatting rules as the U.S., while others allow more than one statement or more than one panel for drug facts content. These differences create challenges for international distribution because a drug product marketed in one country may need changes to meet another country’s format and content requirements. For example, certain allergy alert or dosage warning statements that are optional in one country might be mandatory in another. Manufacturers distributing OTC medicines globally must study each applicable OTC drug monograph, adjust packaging techniques intended for different markets, and ensure that both the immediate container label and the subsequent horizontal line layouts comply with each jurisdiction’s rules. Strategic compliance planning and consultation with regulatory experts can help ensure smooth market entry without costly relabeling or product holds. What Are the Consequences of Not Following OTC Drug Label Requirements? Failure to comply with OTC drug label requirements can trigger serious legal and financial repercussions for any company marketing an over-the-counter (OTC) drug. Under the Federal Food, Drug, and Cosmetic Act, an OTC drug product that fails to meet the applicable OTC drug monograph or that does not display required information in the mandated OTC labeling format may be considered “misbranded.” This can result in product recalls, seizure of goods, injunctions, or civil penalties. Beyond fines and legal sanctions, companies risk losing consumer trust and damaging brand reputation. OTC medicine labels are designed to help consumers safely use nonprescription drug products without medical supervision, and if a label’s drug facts, dosage warning, or dosage directions are inaccurate, it could lead to adverse events, hospitalizations, or even fatalities. For example, a drug product marketed without the appropriate dosage unit or with incomplete additional bulleted statements appearing under the appropriate heading could necessitate immediately discontinuing use and generate public backlash. How to Ensure Compliance with OTC Drug Label Requirements Compliance begins with strong internal review and quality control processes. Every OTC drug product, whether a topical drug product or oral medication, must be checked against the applicable OTC drug monograph and other OTC drug regulations to ensure all mandatory statements are present. This includes verifying that the drug facts labeling appears in the proper order, using horizontal barlines and the same horizontal line spacing, and that the subsequent panel immediately follows the first panel with no omissions. Working with regulatory consultants or legal experts who specialize in OTC drug regulations can help companies navigate complex labeling provisions and packaging techniques intended to prevent the drug from undergoing chemical change. Periodic updates and audits are also essential, especially when format and content requirements change or when a modified form intended for a specific market must be adopted. Global distribution may require more than one panel or more than one statement to satisfy labeling provisions in other jurisdictions. Furthermore, the use of specialized labeling software and tools can ensure that every immediate container label and outside container meets FDA standards. This includes properly displaying the common or usual name, net quantity, inactive ingredients, and a toll-free number for reporting complaints. Software can assist in applying the correct format without errors when an approved drug application necessitates a different layout. Finally, hiring a healthcare lawyer is important. Your healthcare lawyer guides you through every stage of compliance, from reviewing your proposed labeling to helping you respond to FDA inquiries. They ensure your drug product labeling stays fully compliant and your brand remains protected. How Do OTC Drug Label Requirements Differ from Prescription Drug Labels? While both OTC drug label requirements and prescription drug labeling are regulated under the Federal Food, Drug, and Cosmetic Act, their regulatory standards differ in important ways. Over-the-counter (OTC) drug products are governed by the applicable OTC drug monograph or, in some cases, by an approved drug application. These regulations mandate the standardized Drug Facts labeling format, which dictates how the drug facts labeling appears, the placement of horizontal barlines, the same horizontal line spacing between sections, and the use of boxed statements. Prescription drug labels, on the other hand, are not formatted with the same consumer-friendly drug facts panel. Instead, they follow a detailed package insert format intended primarily for healthcare professionals. This means that the principal intended actions, dosage directions, stated dosage units, and potential interactions are explained in medical language, often requiring prior diagnosis and professional interpretation. In prescription labeling, the healthcare provider serves as the intermediary, interpreting the drug product labeling and instructing patients on safe use, whereas OTC medicines must provide all necessary directions directly to the consumer. OTC labeling requirements also focus heavily on immediate consumer comprehension, with the principal display panel, net quantity, active ingredient, inactive ingredients, and toll-free number for complaints clearly visible on the immediate container label and outside the container. Prescription labels rely more on pharmacist counseling, making consumer accessibility and the level of detail presented in OTC medicine labels a distinct regulatory and design challenge. How OTC Drug Label Requirements Affect Consumers and Manufacturers For consumers, well-designed OTC medicine labels deliver clear and accurate information needed to use nonprescription drug products safely without a doctor’s supervision. Compliance with the applicable OTC drug monograph ensures that dosage warnings, appropriate dosage units, and other required statements are present. This improves safety by alerting users to conditions that would necessitate immediate discontinuation of use, such as severe allergic reactions or adverse effects tied to liver damage, as communicated through a separate allergy warning or liver warning. For manufacturers, OTC drug regulations carry both legal and financial implications. Failing to follow the OTC labeling format, omitting required statements, or using an improperly modified form intended for a specific market can render a drug product marketed in violation of FDA labeling provisions. This could trigger recalls, fines, or even prevent the product from entering new markets, particularly where more than one statement or more than one panel is required under other OTC drug regulations abroad. Packaging techniques intended to preserve stability and prevent the product from undergoing chemical change are also closely scrutinized. From a marketing perspective, OTC drug label requirements influence how brands design their principal display panel and overall packaging. The format and content requirements dictate the exact placement of the active ingredient, principal intended actions, and net quantity, while maintaining compliance with spacing rules like the subsequent horizontal line or horizontal barline immediately preceding each section. Where Can I Find an OTC Label Template? Finding a reliable OTC label template is essential for creating compliant over-the-counter (OTC) drug product packaging that meets FDA format and content requirements. The U.S. Food and Drug Administration provides sample label illustrations and guidance documents showing how drug facts labeling appears. This includes the proper OTC labeling format, a horizontal barline immediately preceding each section, the same horizontal line spacing, and the placement of mandatory warnings like the asthma alert, sore throat warning, stomach bleeding warning, liver warning, and separate allergy warning. These resources, along with the applicable OTC drug monograph, help manufacturers design labels that include the active ingredient, the appropriate dosage unit, the stated dosage unit, the principal intended actions, the dosage warning, and all additional bulleted statements appearing under the appropriate heading. For companies seeking efficiency, several regulatory compliance vendors and labeling software platforms offer downloadable OTC medicine labels in editable formats. These templates can be customized to match the principal display panel size, net quantity, immediate container label specifications, and other OTC drug regulations. Customization is important because each nonprescription drug product is likely to have unique requirements under its OTC drug monograph. They might include special packaging methods to keep the drug stable, multiple panels for different languages, or a different design for specific topical or spermicide products. In addition, working with a healthcare lawyer or regulatory consultant ensures that your customized label follows the correct format and content requirements, bears the labeling means as required, and includes every mandated element, from the toll-free number to report complaints to the inactive ingredients listing. At Cohen Healthcare Law Group, we can help review your proposed labeling to ensure compliance before your drug product is marketed, avoiding costly redesigns or enforcement action. Want to Ensure OTC Drug Label Compliance? OTC drug label requirements are set by the FDA to ensure that over-the-counter (OTC) drug products give consumers the information they need to use them safely and effectively. Proper OTC medicine labels must clearly show the main uses, amount of product, inactive ingredients, and a toll-free number on both the main container and any outer packaging. Compliance with these requirements protects public safety, prevents misuse, and shields manufacturers from legal and financial risks. FAQ When it comes to over-the-counter (OTC) drug labeling, the rules are strict to ensure consumer safety. Below are answers to some of the most common questions about OTC drug labeling compliance: What Are the FDA Requirements for OTC Drugs? The FDA requires OTC drug products to follow the applicable OTC drug monograph or obtain an approved drug application. The drug facts label must be presented in a standardized format and include specific content, such as the active ingredient, dosage unit, uses, warnings, and directions. Labels must also meet format and content requirements under the Federal Food, Drug, and Cosmetic Act. Can OTC Drug Labels Be Changed Without FDA Approval? If the change is consistent with the applicable OTC drug monograph and maintains compliance with all OTC drug regulations, FDA pre-approval is generally not required. However, changes that alter active ingredients, principal intended actions, or safety warnings may necessitate additional review. How Often Do OTC Drug Labels Need to Be Reviewed? Manufacturers should review OTC medicine labels periodically to ensure they meet current FDA labeling provisions and reflect any updates to the OTC drug monograph. Reviews are also essential when new safety data emerges or when packaging techniques are intended for stability changes. What Penalties Exist for Non-compliance With Labeling Requirements? Non-compliance can lead to product recalls, fines, injunctions, or seizure of goods, and in severe cases, legal action for misbranding under the FD&C Act. These penalties can damage both consumer trust and brand reputation. Are There Specific Font Size and Style Requirements for OTC Drug Labels? Yes, the FDA’s OTC labeling format rules specify minimum font sizes, easy-to-read type styles, and spacing, along with horizontal barlines and the same horizontal line separation between sections. Certain warnings, like a liver warning or asthma alert warning set, may also require a box and red letters for emphasis. What Are the Three Criteria That Must Be Met by an OTC Drug? An OTC drug must be safe and effective for self-use without medical supervision, have labeling that provides clear drug facts and dosage directions, and contain active ingredients recognized as safe and effective under the applicable OTC drug monograph.
August 23, 2025
Labor and Employment
Pregnancy and Lactation in the Workplace: Employer Duties Under Federal Law
August is the most popular birth month in the U.S., meaning many employees will return from parental leave this fall and winter with new postpartum needs. Two key federal laws – the PUMP Act and the Pregnant Workers Fairness Act (PWFA) – shape the legal obligations employers must provide to nursing employees and others with pregnancy-related conditions. Understanding these laws is essential for compliance and creating a supportive workplace for new parents. PUMP Act The Providing Urgent Maternal Protections for Nursing Mothers Act (“PUMP Act”), 29 U.S.C. § 218d, signed into law in December 2022, expands protections under the Fair Labor Standards Act (FLSA) for employees who need to express breast milk at work. The PUMP Act requires that employers provide reasonable break time, whenever needed, for an employee to express breast milk for her nursing child during the first year after birth and prohibits denying a covered employee a necessary pumping break. The law also requires employers to provide a space, other than a bathroom, that is shielded from view and free from intrusion by coworkers and the public. These protections apply to nearly all FLSA-covered employees; however, certain employees of airlines, railroads, and motorcoach carriers are exempt from the law, and employers with fewer than 50 employees are not subject to the break time and space requirements if compliance would impose an undue hardship. Even so, employees who are exempt under federal law may still be entitled to protections under state or local laws. The PWFA The Pregnant Workers Fairness Act, 42 U.S.C. §§ 2000gg to 2000gg-6, effective June 27, 2023, requires covered employers to provide reasonable accommodations for known limitations related to pregnancy, childbirth, or related medical conditions, unless doing so would cause undue hardship. Examples of reasonable accommodations under the PWFA include modified work schedules to allow for pumping, additional breaks beyond those required by the PUMP Act, and temporary changes in duties to reduce postpartum physical strain. The PWFA covers private and public sector employers with 15 or more employees, Congress, federal agencies, employment agencies, and labor organizations. 42 U.S.C. § 2000gg(2). Employers can take several proactive measures to comply with the PUMP Act and PWFA while supporting pregnant, nursing, and postpartum employees. Employers should start by reviewing and updating workplace policies to ensure they reflect the requirements of both laws, including clear procedures for requesting accommodations and designating appropriate lactation spaces that meet the PUMP Act standards for privacy and accessibility. Employers should also have processes in place to ensure that managers, supervisors, and HR personnel understand how to promptly respond when an employee raises a pregnancy- or postpartum-related need or accommodation request. Finally, maintaining open communication with employees returning from parental leave by proactively providing information on their rights and the resources available to them can help prevent misunderstandings, reduce legal risk, and foster a more supportive and inclusive workplace culture.
August 22, 2025
Bankruptcy
Fifth Circuit Confirms Third-Party Liens Survive Chapter 11 Discharge
The Fifth Circuit has confirmed the old adage that liens “ride through” bankruptcy regardless of a discharge. Reversing a Texas bankruptcy court, the Circuit Court has held that a statutory privilege (a lien) against property of a non-debtor cannot be extinguished by a Chapter 11 discharge or by a plan provision stating that the underlying claim is “settled” or “satisfied” by the plan’s payments. In In re Dynamic Offshore Res. NS, L.L.C., 2025 WL 1651901 (5th Cir. June 11, 2025), the panel reversed the Bankruptcy Court for the Southern District of Texas and held that an oil driller’s “statutory privilege” under Louisiana law to a lien against an oil well site’s owner or lessee was not extinguished by the Chapter 11 discharge or the confirmed plan’s provisions that creditors’ payments are in “settlement” and “satisfaction” of their claims. The debtor, Fieldwood, an oil well operator, had failed to pay a driller $13 million for its services prior to the bankruptcy case. The driller sought to enforce its statutory privilege against the site lessee under Louisiana law, but the lessee argued that the confirmed plan, which discharged the debt and indicated confirmation constituted a “satisfaction’ of the claim, meant the lien could no longer be enforced. Of course, the “black letter” rule that a lien “rides through” bankruptcy regardless of discharge would seem to apply. The twist was that under the “Louisiana Oil Well Lien Act” (LOWLA), the “privilege [was] extinguished ... [u]pon extinction of the obligation it secures.” So, the debtors were able to argue that, if the discharge or confirmed plan rendered the debt “extinct,” then the lien must be extinguished as well. They managed to get the bankruptcy court’s attention. After first ruling that the lien was not extinguished, Judge Isgur reversed himself and found that the obligation was rendered “extinct” by the discharge and plan provisions stating that creditor payments were in “settlement” and “satisfaction” of claims. A settlement and satisfaction, Judge Isgur reasoned, meant that the obligation ceased to exist, meaning the privilege must be extinguished. On appeal, the court noted the well-known rule that a discharge does not extinguish a claim but simply operates as a permanent injunction against its collection. So, the discharge couldn’t be grounds for extinguishing the lien under Louisiana law. The panel then noted that plan’s “settlement” and “satisfaction” language applied only to the relationship between the creditor and the debtor and cannot release a third-party from the underlying lien rights. Taking its cues from Purdue, the panel stated that not only were non-consensual release provisions generally prohibited by the code, but that no third-party release could arise from general language such as “settlement” or “satisfaction,” because such releases must be stated specifically in the language of the plan.
August 21, 2025
Sports Entertainment and Media
Federal Court Rules SoundExchange Lacks Standing in SiriusXM Royalty Dispute
Judge Naomi Reice Buchwald of the U.S. District Court for the Southern District of New York dismissed SoundExchange's $150 million lawsuit against SiriusXM, finding that the performance rights organization lacks legal standing to pursue litigation against broadcasters. The August 7, 2025, decision centered on allegations by SoundExchange, a non-profit entity designated by Congress as the singular entity responsible for collecting and distributing digital performance royalties for sound recordings, that SiriusXM manipulated its revenue accounting to shortchange artists on royalties stemming from the company’s satellite radio services. SoundExchange based its suit primarily on Section 114 of the U.S. Copyright Act, and claims that the underpaid royalties by SiriusXM have climbed since filing the initial suit in 2023, now allegedly exceeding $400 million. Judge Buchwald's opinion concluded that while Section 114 of the Copyright Act designates SoundExchange as the authority for collecting and distributing digital performance royalties, Congress never explicitly granted the body a private right to enforce nonpayment through litigation —unlike Section 115 — which expressly confers similar litigation powers to The Mechanical Licensing Collective. Notably, Judge Buchwald did not specifically address the merits of SiriusXM’s alleged nonpayment, restricting analysis solely to the threshold issue related to Section 114 of the Copyright Act, potentially leaving a door ajar for further enforcement by SoundExchange. SoundExchange disputed the ruling, calling Judge Buchwald's interpretation "entirely wrong on the law" and argued that Congress's inclusion of the word "enforcement" in Section 114 necessarily implies litigation authority. The organization contends that being charged with collecting and distributing royalties without the ability to bring legal action against non-compliant licensees would undermine the entire statutory licensing framework's function and efficiency. SoundExchange also points to practical precedent, noting as well that SiriusXM has acknowledged in prior disputes that SoundExchange reserves the right to sue for compliance. The ruling may have broader implications beyond the immediate SiriusXM case, affecting SoundExchange's enforcement capabilities across the digital music industry, including pending lawsuits against Napster and Sonos for similar nonpayment. SoundExchange is considering an appeal to the Second Circuit and potentially filing actions in state courts to preserve its enforcement mechanisms. The case presents a fundamental question about Congressional intent in creating the modern digital music licensing framework and whether administrative efficiency requires corresponding enforcement authority, with the resolution likely to have lasting implications for the balance of power between streaming services and rights holders in the music industry.
August 20, 2025
Family Law
Can You Start Dating While Divorcing? Legal and Personal Considerations
When couples agree to divorce, one of the first questions that is often asked is: “Can I start dating?” The simple answer is yes you can, but there are things to keep in mind. Even after you’ve filed for divorce, you are still legally married until a judge signs the final divorce papers. That means dating is technically “dating while married.” In most cases today, this won’t stop your divorce from going through. But it can impact issues like custody arrangements, financial matters, and how smoothly the proceedings unfold. If you have children, the court is always focused on what’s best for them. Dating amid a divorce often prompts questions such as: Is the new partner being introduced too soon Does the new relationship disrupt the children’s routine Is it adding stress or confusion for the kids Is the new partner reputable, a criminal, a public figure, etc. Judges want to see stability. Even if you feel ready to move forward, the court may see early dating as a potential distraction from your children’s needs. One of the biggest financial pitfalls of dating during divorce is something called “dissipation of marital assets,” which is a legal way of saying: spending money that belongs to both spouses on things outside the marriage, without your spouse’s consent. Examples include: Buying gifts for a new boyfriend or girlfriend Paying for trips, meals, or hotels with marital funds Using joint accounts for entertainment, rent, or travel related to the new relationship If the court finds that money was spent in this manner, the spouse responsible may be required to “pay it back” by giving the other spouse a larger share of the remaining assets. There are other practical concerns. For instance, negotiations may become more challenging. If your spouse finds out you’re dating, they may feel hurt or angry, which can make reaching an agreement more difficult. Dating while married can be emotionally messy. Divorce already comes with a lot of stress. Adding a new relationship may complicate your own healing process. If you start dating, children must come first. They may need time, as children often struggle with change. Bringing a new partner into their lives before the dust settles may make things harder on them. Tips if You Do Decide to Date Don’t use joint or marital funds on the new relationship Keep your dating life private until after the divorce is finalized Wait to introduce a new partner to your children until things are more settled or you’ve discussed a process with a mental health professional Talk with your lawyer about how dating might impact your specific case There isn’t a law that outright bans dating during a divorce, but between possible custody concerns, financial risks like dissipation, and the emotional toll, it often does more harm than good. If you want the divorce process to go as smoothly as possible, and protect your finances and your kids, the safest choice is usually to wait until the divorce is final before jumping back into dating.
August 19, 2025
Estates and Trusts
Planning and Parting Wisdom to Consider for Your College-Bound Children
Sending a child off to college is a major milestone — one filled with pride, excitement, and, in my case, a little anxiety. Two years ago, I sent my eldest to Europe for her university experience and, while my second is staying in the U.S., she is headed south this fall. I am sorry to report to the parents sending their child off for the first time that it does not get any easier. As parents, we spend years preparing them emotionally for this next chapter. But there’s another critical aspect of preparing them to fly the nest that often gets overlooked: legal documents and related planning. Once your child turns 18, you no longer have automatic access to their medical records, financial accounts, academic records, and in some states, you do not even have the right to make decisions on their behalf in an emergency. Without certain legal documents in place, you may be powerless in a situation where your guidance, input, and authority are most needed. Healthcare Proxy (sometimes referred to as a Medical Power of Attorney) A Healthcare Proxy allows your eighteen-year-old child to appoint someone (usually a parent) to make medical decisions on their behalf, in the event that they cannot articulate their wishes to care providers. This is crucial in emergency situations. Without this document, and pursuant to the Health Insurance Portability and Accountability Act (HIPAA), medical professionals are prevented from sharing any information, even with you, about your child’s condition. HIPAA Authorization Form HIPPA protects your eighteen-year-old child’s privacy once they are legally an adult. A HIPAA Authorization form specifically allows healthcare providers to release medical information to you, giving you the ability to communicate with doctors, access medical records, and be informed in case of an emergency. Durable Power of Attorney (POA) A POA empowers you, or whomever your child names, the authority to handle their financial matters. This can include managing bank accounts, signing tax returns, handling financial aid or tuition payments, and more, either on a temporary or ongoing basis. A POA is invaluable if your child is studying abroad, facing a logistical emergency, or simply needs help managing administrative tasks while adjusting to college life. FERPA Release Form The Family Educational Rights and Privacy Act (FERPA) limits a parent’s access to their child’s educational records (grades, disciplinary actions, tuition bills, etc.) once the child turns 18 or attends a postsecondary institution. If your child signs a FERPA release form, it authorizes the college to communicate with you directly about their academic records. Many universities provide this form during orientation, but it’s important to ask proactively. Digital Assets and Passwords University students, like all their peers, live much of their lives online. From email accounts to social media to online banking and cloud storage, ensuring a trusted individual has access to these digital assets in case of emergency is often overlooked. Encourage your child to create a secure list of important passwords or use a password manager that can grant emergency access to trusted individuals. Lists of passwords should never be stored on a phone or similar device that can be accessed by those who are not the appointed trusted individuals. Health Insurance Considerations When my child attended university in Europe, we discovered that her health care would be covered by university while in Europe. Still, we had to review her existing coverage here in the U.S., to ensure she still had coverage when she was home. It is imperative to verify whether your child will remain on your health insurance plan or if the university requires participation in a student health plan managed by the university. Sometimes the options provided by the university are more economical or make more sense if the university is far away and the plan has local coverage. If your child remains on your health care insurance, they should have at least a copy of their health insurance card. They should also understand how to locate in-network providers near campus and know the process for seeking care away from home, so that you are not stuck with a large medical bill from an out-of-network provider. Emergency Contacts and Local Resources Ensure your child’s phone has updated emergency contacts. It is recommended that named emergency contacts should be designated as such in their phone so others can assist in contacting you, if needed. In addition, make sure that your child has the names and locations of local, reputable urgent care centers, hospitals, dentists, mental health providers off campus, and pharmacies near their university. Emergencies are, by nature, unpredictable. In a crisis, the last thing you want is to be delayed by red tape. Having these documents in place not only gives you peace of mind but also empowers your child to step into adulthood with a well-prepared safety net. This is also a great opportunity to introduce your child to the concept of planning, in general, which is a personal responsibility and something to consider as they join the ranks of legal adulthood. By having these conversations now, you are not just preparing for emergencies, you are equipping them with the mindset of proactive life planning. Providing the tools to handle their newfound independence is one of the best send-off gifts you can give.
August 19, 2025
Family Law
Who Controls the Money Doesn’t Control the Divorce
It’s very common in a marriage for one spouse to earn most of the income or handle all the financial decisions. But when divorce happens, the spouse who hasn’t managed the money often feels anxious or powerless. The good news is that the law provides protections to make sure both spouses are treated fairly, regardless of who made or controlled the money. During a divorce, both spouses must provide full financial disclosure. That means: Listing income, bank accounts, retirement accounts, investments, and debts Producing tax returns, pay stubs, and account statements Explaining assets like real estate, businesses, or pensions Even if your spouse controlled the accounts during the marriage, they must disclose everything in the divorce. If they try to hide assets, courts can impose penalties or sanctions. Courts understand that one spouse may need money to get by while the divorce is pending. The dependent spouse has options like asking the court for: temporary spousal support (sometimes called “pendente lite” support) to cover living expenses until the divorce is final access to marital accounts to use for reasonable living expenses during the divorce, as long as money isn’t wasted attorney’s fees if one spouse has no access to funds to pay toward attorney’s fees, so both sides can participate fairly In most states, marital property includes income and assets acquired during the marriage — even if only one spouse earned the paycheck. That includes retirement accounts, savings, and property bought during the marriage, which are usually divided fairly (though not always 50/50), and debts, like mortgages or credit cards, are also divided. So even if you didn’t control the finances, you still have a legal claim to your share of what was built during the marriage. If one spouse has been financially dependent on the other, the court may award spousal support. This is not formulaic in most jurisdictions, and instead is based on factors such as: Length of the marriage Each spouse’s income and earning ability Standard of living during the marriage Contributions to the household (including childcare and homemaking) Health of each spouse Age of the parties Cause of the breakup of the marriage The goal is to ensure a fair transition, particularly for spouses who have given up career opportunities to support the family. Before or during the divorce process, the dependent spouse can take steps to protect themselves. For instance, collect as much financial documentation as possible, copy it, and provide it to their lawyer. Inform your lawyer if you are aware of assets, even if you do not have access to the records. If possible, avoid using credit cards to survive. Taking on debt may lead to future complications, speak with your attorney about safer alternatives. If your spouse made all of the money and managed the finances, you are not at their mercy in divorce. The law requires financial transparency, gives you the right to a fair share of marital assets, and provides ways to make sure you have the financial support you need during and after the process. You don’t need to have been the “breadwinner” to be treated fairly in a divorce.
August 19, 2025
Healthcare
Health Care Proxy vs Durable Power of Attorney
A health care proxy, also called a medical power of attorney, is a legal document that allows you to appoint someone as your “health care agent.” This agent makes medical decisions for you if you become incapacitated or unable to speak for yourself. On the other hand, a Durable Power of Attorney (DPOA) allows you to authorize another person as your “agent” or “attorney-in-fact.” This person is to make financial and legal decisions on your behalf. The “durable” part means this power continues even if you become mentally or physically incapacitated. This article will explain the key differences between a health care proxy and a durable power of attorney. It will also discuss when you might need both. What Is a Health Care Proxy? A health care proxy is a legal document that authorizes a trusted person to make medical decisions on your behalf if you’re unable to do so. It could be a family member, close friend, or another individual you choose. This situation typically arises when you’re incapacitated, such as after a serious accident, during surgery, or in end-of-life care situations. Health care proxies are vital tools in ensuring that your healthcare decisions are respected, especially if you cannot communicate your wishes to a doctor or medical provider. The person appointed under a health care proxy, known as your health care agent, will have the authority to make specific healthcare decisions, such as choosing treatments, consenting to or refusing surgeries, and determining whether to continue life-sustaining treatment like life support. The agent is expected to act based on the principal’s wishes or previously provided specific instructions. Often, they may consult a living will or advance directive to guide their decisions. It’s important to note that this authority is generally limited to health care decisions and does not extend to financial or legal matters. Each state may have different legal requirements for establishing a valid health care proxy, but in most cases, the document must be signed in the presence of witnesses or a notary. What Is a Durable Power of Attorney? A durable power of attorney is a legal document that allows a person (called the “principal”) to appoint another individual (the “agent” or “attorney-in-fact”) to handle a broad range of financial, legal, and in some cases health-related matters on their behalf. This legal document remains valid even if the principal becomes incapacitated, which is why the term “durable” is used. In contrast to a general power of attorney, a durable version is specifically designed to remain in effect during times when the individual is unable to make their own decisions. Depending on how it’s drafted, a durable power of attorney can take effect immediately upon signing, or it can be a springing power, which activates only under certain circumstances, such as a medical diagnosis of incapacity. The scope of authority granted under this document can be extensive. If explicitly included, it can encompass managing investments, signing checks, contracts, handling tax matters, and even making healthcare decisions. This document plays a vital role in an estate plan, as it ensures that someone can act in your best interest if you’re unable to manage your affairs. Durable Power of Attorney vs Health Care Proxy When planning for unexpected life events, understanding the key differences between a health care proxy and a durable power of attorney is essential. Both are legally binding documents that authorize someone else to make decisions on your behalf, but they serve very different functions. While one focuses on medical care and healthcare decisions, the other addresses financial responsibilities, signing contracts, and managing legal affairs. Together, they form a vital part of an effective estate plan and ensure your principal’s wishes are respected in various circumstances, especially when you are unable to communicate or make your own decisions. Type of Decisions They Cover A health care proxy gives your chosen health care agent the authority to make medical decisions for you, but only if you become permanently incapacitated or unable to make those decisions yourself. These health care decisions may include choices about treatment, surgery, medication, or whether to continue life-sustaining treatments, such as life support. The agent is expected to act in accordance with your healthcare decisions, often informed by a living will or other advance directive that expresses your wishes clearly. In contrast, a durable power of attorney is a legal document that gives your attorney-in-fact or agent broad authority to handle financial decisions, legal responsibilities, and sometimes even healthcare needs, if explicitly granted. This authority may cover everything from managing investments to signing checks to even selling property to dealing with taxes and insurance. While the healthcare power is usually separated into a care proxy, some states allow a durable power of attorney to include both healthcare power and financial authority, depending on how the document is drafted. When They Apply Another major difference between a care proxy and a durable power of attorney lies in when these legal documents take effect. A healthcare proxy only becomes valid under certain circumstances, typically when a doctor confirms that the person is unable to make their own decisions regarding medical care. This often occurs in the context of a serious illness or injury or at the end of life, when clear healthcare decisions must be made, but the patient can no longer communicate. On the other hand, a durable power of attorney can be structured in different ways. It may be active immediately upon signing, or it can include a springing power clause that activates only if the person becomes incapacitated. This flexibility makes it a powerful tool in a variety of situations, particularly when planning for aging, chronic illness, or potential cognitive decline. It ensures someone you trust has the legal authority to act on your behalf without delay. Legal Requirements and Forms Both a health care proxy and a durable power of attorney are considered critical legal documents, but their execution varies by state. Each state has its own state-specific forms and requirements around witnessing or notarization, which means it’s essential to work with a legal professional who fully understands local laws. Some states even allow you to combine both powers into one unified medical power of attorney, which can streamline your documentation while ensuring your wishes are honored in all areas. When choosing a person to act on your behalf, it’s important to select someone who understands your values and is willing to follow your specific instructions. Some individuals may have strong feelings about end-of-life care or want to give limited power to the agent, depending on the situation. You can also appoint the same person to act as both your health care agent and financial agent under a durable power of attorney, or choose different people for each role if that better aligns with your needs and comfort level. Comparison Table: Health Care Proxy vs Durable Power of Attorney Feature / Aspect Health Care Proxy Durable Power of Attorney Primary Purpose Makes medical decisions for you Handles financial, legal, and sometimes medical matters Scope of Authority Healthcare decisions only Broad — finances, property, legal, and possibly medical When It Takes Effect Usually, only upon incapacity for medical decisions Can be immediate or upon incapacity Duration Ends when you regain capacity or upon death Remains valid until revoked or upon death Legal Requirements Typically requires witnesses Usually requires notarization Common Alternate Names Medical Power of Attorney, Health Care Agent Financial Power of Attorney Chosen Agent’s Role Advocate for your medical preferences Manage finances, pay bills, sign contracts, and handle property Who Needs It Anyone who wants a trusted person to make medical decisions if incapacitated Anyone who wants a trusted person to handle finances/legal matters Risk of Not Having It Doctors may have to make decisions without knowing your wishes Bills may go unpaid, assets unmanaged, and legal matters stalled Should You Get Both a Proxy and POA? When it comes to protecting your future, the smartest choice is often to establish both a health care proxy and a durable power of attorney. These two legal documents serve different functions, ensuring full coverage of medical decisions and financial responsibilities If you only have a health care proxy in place, you may find that no one has the authority to pay your bills, manage your assets, or handle urgent financial matters while you’re incapacitated. Likewise, if you only have a durable power of attorney, your agent may be powerless to make critical healthcare decisions in a hospital setting, especially if the document does not include specific healthcare power. In high-stakes medical situations, these gaps can lead to confusion, legal delays, and added stress for your family members. That’s why most legal professionals recommend having both documents as part of your estate plan, ensuring that your principal’s wishes are followed in all circumstances. How to Choose the Right Healthcare Lawyer Choosing the right legal professional to help you draft your health care proxy and durable power of attorney is essential. Not all attorneys have experience with healthcare law, and a mistake in your documentation could create problems during emergencies. Look for an attorney who: Specializes in healthcare law, estate planning, and legal documents related to healthcare decisions and financial planning. Has specific experience preparing both health care proxies and durable powers of attorney, as these documents must work together without conflict. Understands your state’s specific requirements for witnesses, notarization, and the scope of authority granted under each document. Takes time to understand your unique medical, financial, and personal wishes and helps you create clear, specific instructions. Can explain the key differences between different types of power of attorney and guide you in selecting the right person appointed to act on your behalf. A qualified healthcare lawyer will make sure your documents are clear, legally valid, and aligned with your principal’s wishes. Most importantly, they will ensure your plans remain enforceable in various situations, including medical emergencies, cognitive decline, or permanent incapacity. How to Create a Health Care Proxy and Durable Power of Attorney The first step is to choose the right agent for each role. This can be a family member, close friend, or trusted person who understands your values and will respect your wishes. You may select the same person for both your care proxy and durable power of attorney, or you may appoint different people depending on the different powers each role requires. It’s important to select someone who is capable of making tough decisions and who can handle medical care or financial decisions during emergencies or under stress. Next, you’ll need to complete the proper state-specific forms for both documents. These forms typically outline the scope of authority, any specific instructions, and the circumstances under which the documents take effect. For example, your healthcare proxy may only become active if you are declared permanently incapacitated by a doctor, while your durable power of attorney could be active immediately or upon a triggering event (a springing power). Be sure to consult a legal professional who understands the legal responsibilities associated with each document and who can ensure compliance with your state’s requirements. Many states require that these documents be notarized or witnessed by one or more adults who are not agents. These requirements help protect against fraud and ensure that the principal’s wishes are clearly documented. A mistake in the witnessing or notarization process could render the document invalid, which is why it’s important to fully understand what your state law mandates. Once the documents are completed and signed correctly, they should be stored in a safe but accessible location. Provide copies to your appointed health care agent, your attorney-in-fact, your primary doctor, and perhaps a family member or legal advisor. You should also keep a copy of your estate plan. In some cases, it may be wise to register your healthcare proxy with your state or healthcare provider, particularly if your healthcare decisions are complex or involve end-of-life care. Need a Lawyer for Your Proxy and POA? When you’re incapacitated, a health care proxy enables a trusted individual to make medical decisions on your behalf, while a durable power of attorney grants someone the authority to manage financial and legal matters. Occasionally, they even make certain healthcare decisions if specifically stated in the document. These are two completely unique powers, and together, they provide full coverage for your medical care, end-of-life care, and financial responsibilities in a variety of situations. Creating these legal documents now ensures that your own decisions and the principal’s wishes are honored no matter what the future holds. Keep in mind that relying on verbal agreements or outdated forms can lead to delays, confusion, or legal battles at a time when clarity matters most. FAQ Understanding the difference between a healthcare proxy and a durable power of attorney can be confusing, especially when it comes to how they function in real-life medical and legal situations. Here are some answers to the most common questions to help you make informed decisions: Does a Power of Attorney Override a Healthcare Proxy? No, a durable power of attorney does not override a health care proxy; they cover different areas. The proxy controls medical decisions, while the POA handles financial and legal matters, unless healthcare powers are explicitly included. Is a Durable Power of Attorney the Same as a Healthcare Proxy? No, they are two different legal documents. A durable power of attorney manages financial decisions, while a healthcare proxy is limited to medical care and healthcare decisions if you’re incapacitated. What Are the Disadvantages of a Healthcare Power of Attorney? One potential drawback is that it only takes effect when you’re deemed unable to make your own healthcare decisions, which can cause delays. Furthermore, without clear, specific instructions, your health care agent may face difficult choices without knowing your exact wishes.
August 19, 2025
Commercial Litigation
Three Key Tips for Drafting Strong Discovery Requests
The discovery phase of a case is critically important. Navigating a case appropriately through the discovery stage can lead to achieving favorable settlement terms, disposing of the case by summary judgment, or prevailing at trial. Thoughtfully crafting discovery requests is one of many tactics that maximize the chances for success. Keep these three points in mind when preparing discovery requests. Tailor the requests to the claims and defenses. Consider the elements for each claim and then the elements for each defense when drafting the requests. If the requests cover each element in an individualized manner, the door opens to potentially disposing of the case at the summary judgment stage. This approach leads to the parties exchanging relevant documents and information and allows them to digest each other’s theory of the case, minimizing the chances for a surprise at trial. Further, when both sides disclose documents and information, they also end up revealing the strengths and weaknesses of their respective claims or defenses. By identifying those strengths and weaknesses, the parties can more readily identify the components of the case, where they have leverage, and become more likely to come to a settlement (which saves the parties valuable time and resources). Pursue potential evidence to use to impeach witnesses’ credibility and to flesh out the theory of the case. Once you have your theory of the case, discovery is the time to further develop that theory by bringing out the context of the case. No case should take place in a vacuum. Typically, parties have ample evidence the other side can use (e.g., at trial) to illustrate the theory of the case. In a breach of contract case, for instance, it may be helpful to request documents or information about other contracts the party held at the time or the benefits that a party obtained when it breached the contract. In response to the request, you may receive a document that shows why the party breached the contract — a helpful piece of context that you can use at trial to better tell your client’s story and diminish the other party’s credibility. Although each case is factually distinct, there are always pieces of evidence that can be used for these purposes, which may make the difference in persuading a judge or jury. Include requests for information and documents where the adversary’s lack of a response is useful. Requesting documents and information from the other side that directly relate to the claims and defenses in the case is a great starting point. Adding requests with an eye toward the adversary not providing a response can also be very useful at trial. The lack of a response narrows the universe of evidence that the parties can present at trial, providing you with a more predictable trial and an ability to identify the weak points of your adversary’s case. It also provides the opportunity to flesh out the testimony you wish to elicit from the other side as to the lack of evidence. This can be particularly powerful when you cross-examine the other side’s witness and have that witness testify — in response to a string of questions from you — that they do not have evidence touching on a number of aspects pertaining to the case. Those moments during trial are not only good theater but also highly persuasive.
August 18, 2025
Estates and Trusts
Obergefell in Question: Estate Planning Risks for Same-Sex Spouses
On August 11, 2025, the United States Supreme Court was asked to reconsider Obergefell v. Hodges, the 2015 decision that federally guaranteed marriage equality for all couples. This new case involves the four-times married former Kentucky county clerk who famously denied marriage licenses to same-sex couples in 2015. She argues that her religious freedom should have allowed her to refuse to recognize same-sex marriage and asked the Supreme Court to take up her cause. While many remain cautiously optimistic that marriage equality will not be undone, the fact that the Court may even consider this petition is deeply unsettling for the LGBTQ+ population and their allies. (Axios, Forbes, The New Republic) Why This Matters for Estate Planning A Return to Patchwork State Laws If Obergefell were overturned, the U.S. would revert to a pre-2015 tapestry of laws in which individual states would have the opportunity to determine marriage rights for their own domiciliaries. For those residing in more conservative states, it could mean disaster for same sex spouses. Legal and Emotional Chaos for Families Suddenly, all the rights, protections, and privileges that come automatically with marriage, such as hospital visitation, medical decision-making authority, inheritance, and tax breaks, would once again require lawyers to draft elaborate, and admittedly brittle workarounds. In some states, lawmakers are bound to make those workarounds incredibly difficult to accomplish. Estate Planning Problems MagnifiedTax implications: Without a legally recognized spouse, couples will lose spousal estate tax exemptions at the federal and possibly state levels. Probate exposure: Without the automatic transfer rules of marriage, such as tenancy by the entirety designations on deeds, estates could be forced to go through a full probate proceeding or worse, pass to next-of-kin heirs, and not the spouse. Healthcare proxies and decision-making: Health care directives, such as Health Care Proxies, would need constant updates as cross-state enforcement could become uncertain when an individual’s status is demoted from “spouse” to simply “agent” under a health care directive. It should be noted that the rights of an agent are certainly less secure than spousal rights. Children and parentage issues: The parental presumptions, adoptions, and guardianships may also be under fire and could become contested in ways they have not been observed for a decade. As with documented workarounds for estate planning, it is concerning that parentage could hinge on an estate planning document that is enforceable in one state and not another. In summary, this possibility bears a real human cost if the federal government no longer sees a marriage as valid, and all the financial ease, parental securities, medical protections, and end-of-life comfort assumed to be guaranteed are no longer. Same-sex couples do not just lose a symbolic right to marry — they face disruptions to fundamental life, health, and legacy decisions. This is not just another court case: the ramifications will fundamentally reshape how families, especially those with trans and LGBTQ+ members, plan their lives, protect each other, and preserve their legacies. It is vital we pay attention, share the facts, and act with allyship.
August 14, 2025
Healthcare
Can Medical Offices Go Corporate?
Yes, medical offices can go corporate in certain circumstances, depending on state laws. This typically means shifting from a physician-owned, independent practice to a business structure owned or managed by a corporation, often involving outside investors, healthcare management companies, or larger healthcare networks. This post explains what going corporate means for medical offices and the laws on corporate practice of medicine. It will also let you know the legal issues that may arise when medical offices go corporate. What Does Going Corporate Mean for Medical Offices? When a medical office “goes corporate,” it transitions from being owned and operated by individual physicians to being part of a larger corporate healthcare entity. These entities can include for-profit corporations, private equity-backed groups, or healthcare management companies that oversee operations, business strategy, and sometimes even staffing and clinical workflows. Typically, solo/independent practices are physician-owned, with full control over patient care decisions, operations, and business management. These practices often focus on personalized patient relationships and local community service. On the other hand, corporate-owned practices are managed by business executives or management firms, often with a focus on efficiency, scalability, and standardized protocols. While physicians may still lead clinical care, business decisions are typically influenced or directed by non-physician executives. Examples of corporate medical office models include: Large Healthcare Networks: Hospital systems or integrated healthcare organizations that own multiple clinics and employ physicians. Private Equity Firms or Investment-Backed Groups: Entities that acquire practices to streamline operations and improve profitability. Medical Management Companies (MSOs): Provide administrative, billing, marketing, and compliance services while physicians retain clinical control. Franchise Healthcare Models: Corporate branding and operational systems applied across multiple physician-owned locations. What Legal Issues Arise When Medical Offices Go Corporate? When medical offices go corporate, they must navigate complex legal issues that impact how they operate, deliver patient care, and remain compliant with federal law and state regulations. Some of these legal challenges include: Healthcare Compliance Laws Medical Offices Must Follow Corporate medical offices must comply with key healthcare laws, including the Stark Law, the Anti-Kickback Statute, and HIPAA. These laws regulate physician self-referrals, prohibit certain financial arrangements that could influence medical care, and safeguard patient privacy. The federal government, including agencies like the Federal Trade Commission, closely monitors corporate entities in healthcare to prevent anti-competitive practices and protect patients from harm. Compliance challenges are heightened when private equity firms, private insurers, or large health care providers get involved, as these organizations often operate across multiple states and must meet varying legal standards. Corporate medical offices can maintain compliance and optimize business operations by collaborating with experienced healthcare attorneys. Physician Ownership and Corporate Practice Restrictions In many states, corporate practice of medicine laws restrict non-physicians from owning or controlling physician practices. These rules aim to safeguard patient care from business interests and maintain the professional independence of doctors. However, there are exceptions, especially when hospital systems or primary care networks employ physicians. State-specific regulations vary significantly, and in some cases, corporate entities use management service organizations to handle non-clinical business functions while physicians retain control over medical care. Healthcare lawyers play a key role in navigating these ownership restrictions, helping physicians decide whether to sell, merge, or partner with private companies while staying compliant. Licensing and Accreditation Requirements Corporate ownership of physician offices can impact licensing and accreditation, especially when transitioning from a solo or small group practice to a corporate healthcare structure. Health care providers must ensure that all physicians employed remain properly licensed, that accreditations are maintained, and that clinical standards do not drop during the consolidation process. This is particularly important for primary care practices and specialty groups joining larger health systems or hospital networks. A healthcare attorney can guide corporate medical offices through the legal steps required to maintain their certifications and comply with both state and federal regulations during ownership changes. Patient Privacy and Data Security Under corporate ownership, patient privacy and HIPAA compliance remain paramount. Larger corporations, hospital systems, and private insurers often rely more on centralized electronic medical record systems and shared databases While these systems can improve efficiency and outcomes, they also pose risks of data breaches and misuse of sensitive information. Corporate entities must ensure strong cybersecurity measures, proper employee training, and legal safeguards to protect patients’ personal and medical information. Failure to do so can lead to federal government enforcement actions, fines, and damage to the provider’s reputation. Contractual Obligations and Legal Agreements When medical offices go corporate, the web of contractual obligations expands significantly. Physicians employed under corporate structures often enter into detailed employment agreements, while corporate entities engage in complex management contracts, vendor arrangements, and partnerships with health insurers. Careful negotiation is necessary to ensure fairness, safeguard the physicians’ work-life balance, and align with the corporate entity’s goals without compromising patient care. Healthcare attorneys help structure these contracts so that they comply with law, meet business objectives, and support long-term practice stability. Is Going Corporate Right for Your Medical Office? For physician practices and primary care practices across the country, the question of whether to go corporate has become more pressing over the years. Hospital consolidation, vertical consolidation, and increased involvement from private equity firms, private insurers, and large health systems have changed how healthcare providers operate. The American Medical Association, the Physicians Advocacy Institute, and federal government regulators, including the Federal Trade Commission, have all taken note of the rapid pace of change in medicine. With higher payment rates from Medicare and Medicaid, potential financial incentives from health insurers, and increased access to advanced infrastructure, many physician offices are weighing the benefits and risks of joining corporate entities. Let’s weigh the advantages and disadvantages of going corporate: Advantages of Going Corporate for Medical Offices One of the most appealing aspects of joining corporate entities is the improved financial stability and access to capital that can come from working with hospital systems, private equity, or health care providers with strong business backing. Corporate structures also often allow practices to streamline administrative tasks, reduce overhead, and focus more time on direct patient care. By consolidating resources, physicians employed under these models can enjoy enhanced negotiation power with insurers and suppliers, leading to better contract terms and potentially higher payment rates for services. Larger corporate healthcare providers also tend to offer more opportunities for career growth and professional development for doctors, nurses, and employees, while supporting access to advanced technology and infrastructure that might be cost-prohibitive for solo practitioners. In many cases, consolidation further leads to expanded service offerings and improved access for patients, particularly when corporations invest in expanding primary care networks and specialty services. Potential Disadvantages and Challenges Despite the advantages, going corporate is not without its risks. Physicians often face a loss of autonomy when corporate entities or hospital systems take over, as decision-making processes may shift from doctors to business executives. In some cases, there can be conflicts between corporate goals and patient care priorities, especially when the focus on cost reduction or revenue growth overshadows medical care outcomes. Changes in workplace culture, shifts in management style, and new reporting structures can affect the satisfaction of physicians, nurses, and other healthcare providers. There is also the risk that profits may be prioritized over patient outcomes, creating potential tensions between what is best for patients and what benefits the business financially. Patient perception and trust may also shift when independent physician practices are acquired by larger corporations, especially if patients feel they are receiving less personalized care. How Medical Offices Can Transition to Corporate Ownership While the decision to go corporate can bring improved financial incentives, higher payment rates from Medicare and Medicaid, and increased resources from health insurers and corporations, it also requires careful planning to remain compliant with federal law, state regulations, and industry standards. The transition process is under close watch by the federal government, as well as by the American Medical Association and the Physicians Advocacy Institute. The right legal strategy can help doctors, hospitals, and other health care providers complete the move while maintaining patient care quality, work-life balance for physicians employed, and long-term business stability. Step 1: Legal Assessment and Compliance Review The first step in any corporate transition is a thorough legal review by healthcare attorneys experienced in the corporate practice of medicine. This involves analyzing the relevant state laws, reviewing corporate practice restrictions, and ensuring compliance with regulations that govern health care providers, insurers, and companies involved in the transaction. Attorneys also evaluate whether the proposed structure aligns with both federal and state rules, including privacy laws like HIPAA, and whether the transaction may trigger additional scrutiny from regulators at the federal level or within the state department of health. This stage sets the legal foundation for a smooth transition without risking costly penalties or loss of accreditation. Step 2: Selecting Business Structure & Legal Partnership Once the feasibility is established, the next focus is selecting the right corporate entity, whether a professional corporation, LLC, or another structure, based on state requirements and business goals. Healthcare attorneys guide physician offices through the process, ensuring the structure supports compliance, patient access, and quality of medical care. Legal counsel will draft and review critical contracts, including employment agreements for doctors, shareholder agreements for partners, and payer contracts with health insurers. They also ensure that licensing, accreditation, and privacy laws are met while negotiating terms that safeguard physician autonomy and patient outcomes. Step 3: Contract Drafting, Negotiation, and Regulatory Filings With the corporate entity chosen, the process moves to finalizing agreements and preparing necessary filings for approval by medical boards and other relevant agencies. This includes coordinating the transfer or update of medical licenses and certifications, ensuring that practice operations remain uninterrupted. Regulatory filings must be complete and accurate to avoid delays, especially when federal government oversight or state-level review is required. During this phase, attorneys work closely with all parties, such as doctors, insurers, and corporate buyers, to confirm that every term protects the interests of both providers and patients. Step 4: Compliance Program Implementation and Staff Training After the structural and contractual work is completed, a compliance program must be developed to guide ongoing operations. This includes corporate governance policies, billing compliance standards, and protocols for data security and HIPAA compliance. Attorneys and compliance specialists provide training for all employees, from administrative staff to physicians employed, so that everyone understands regulatory obligations and corporate procedures. This is particularly important when corporate ownership spans multiple hospitals or health systems, where standardization ensures consistent patient outcomes and prevents costly mistakes. Step 5: Closing the Transaction and Ongoing Legal Support The final stage involves executing acquisition or merger agreements, completing financial transfers, and officially transitioning ownership to the corporate entity. Even after the transaction is complete, ongoing legal support is essential for handling audits and disputes and adapting to new regulations at both the state and federal levels. This is especially true in a health care environment where consolidation leads to constant changes in market dynamics, spending priorities, and payment structures. With proper legal oversight, physician practices can create a sustainable corporate model that supports patient care, aligns with regulators’ expectations, and offers long-term benefits for providers, employees, and patients alike. Why Medical Offices Need Healthcare Lawyers to Go Corporate The American Medical Association, Physicians Advocacy Institute, and federal government agencies, including the Federal Trade Commission, have raised concerns about how corporate entities impact patient care, medical costs, and physician work-life balance. With so much regulatory oversight at both the federal and state levels, healthcare lawyers play a critical role in guiding doctors, hospitals, and other providers through the process in a way that safeguards compliance, financial stability, and quality of medical care. A skilled healthcare attorney helps mitigate legal risks by identifying potential compliance pitfalls early and providing proactive counsel tailored to the practice’s needs. This is particularly important when dealing with complex corporate structuring, hospital system partnerships, and regulatory filings involving Medicare, Medicaid, and health insurers. Additionally, attorneys oversee the careful review process to make sure the transition follows federal law, avoids unwanted attention from regulators, and stops expensive lawsuits or fines. They also work to secure smooth contract negotiations, covering everything from employment agreements for physicians employed to payer contracts with health insurance, and service agreements with vendors. Furthermore, attorneys provide strategic advice on dispute resolution, handle compliance audits, and offer ongoing legal support long after the transaction is complete. Want to Ensure Compliance When Going Corporate? Going corporate can be a strategic move for physician practices, primary care practices, and specialty physician offices seeking improved financial stability, access to capital, advanced technology, and streamlined operations. While this transition can bring higher payment rates from Medicare and Medicaid, stronger negotiation power with insurers, and opportunities for career growth, it also comes with significant legal, regulatory, and cultural challenges. Whether medical offices should or can go corporate depends on state-specific corporate practice of medicine laws, federal law, and the unique priorities of the physicians and healthcare providers involved. The decision requires weighing the benefits of joining hospital systems or corporate healthcare providers against potential drawbacks like loss of autonomy, changes in workplace culture, and patient trust concerns. To protect both patient care and long-term business viability, the transition must be handled with precision, compliance, and a clear legal strategy. Frequently Asked Questions The decision to take a medical office corporate raises many questions for physicians, patients, and healthcare providers. Here are answers to some of the most common concerns: Can All Types of Medical Offices Go Corporate? Not all medical offices can go corporate, as state-specific corporate practice of medicine laws may restrict non-physician ownership or control. The rules vary widely, so legal guidance is essential before making the transition. How Does Going Corporate Affect Patient Care? Going corporate can bring better access to technology, resources, and services but may also introduce standardized protocols that impact personalized treatment. The effect depends on how the corporate entity balances efficiency with patient-focused care. Will Doctors Lose Their Independence? In many corporate healthcare models, physicians have less control over business decisions, though they may still retain authority over medical care. The degree of independence depends on contract terms and the corporate structure chosen. Which States Allow Corporate Practice of Medicine? Some states, like Florida and New York, permit corporate ownership of medical practices with certain safeguards, while others prohibit it entirely. Each state’s laws are unique, making compliance checks critical before moving forward.
August 14, 2025
LGBTQIA+
Marriage Equality and the Supreme Court: Preparing for the Unexpected
Big news dropped this week, and it’s one of those stories that makes my phone start buzzing with texts from clients, friends, and family asking: “Could the Supreme Court actually take away marriage equality?” Kim Davis, the Kentucky clerk who famously refused to issue marriage licenses to same-sex couples, has asked the Court to overturn Obergefell v. Hodges, the 2015 decision legalizing marriage equality nationwide. For Davis, the appeal is about religious beliefs, but for LGBTQ+ families, it’s about the security of marriages and rights. Can the Supreme Court Overturn Obergefell? For Davis, the case is based on her personal beliefs and most experts think it’s a long shot to undo marriage equality entirely. Still, this Court has surprised us before. Justice Thomas has already suggested revisiting Obergefell, and the fact that the question is back before the Court is a reminder that the fight isn’t over. What Would Happen if Obergefell Were Overturned? If Obergefell were overturned, some states could stop issuing marriage licenses to same-sex couples almost overnight. Old bans and “trigger laws” are still sitting on the books in many states. However, due to the 2022 Respect for Marriage Act, current same-sex marriages would almost certainly still be recognized nationwide. Under this law, if a same-sex couple is legally married in one state, every other state and the federal government must honor that marriage, even if the couple later moves to a state that bans it. Why Does This Matter if You’re Already Married? Some may assume, “Well, we’re already married, so we’re fine.” Not necessarily. Without Obergefell, certain rights could become more difficult to enforce at the state level, such as hospital visitation, inheritance without a will, or the ability to make medical decisions for your spouse. For families with children, especially when only one parent is biologically related, the stakes are even higher. Steps to Take Now Make your family “court-proof.” Ensure you have legal documents in place, including wills, healthcare proxies, powers of attorney, and guardianship documents for kids. Lock in parental rights. A court order, such as a second-parent adoption, is recommended to make parental rights secure, even when both parents’ names appear on the birth certificate. Know your safe states. In areas with an uncertain record on LGBTQ+ rights, it’s important to know where your family would be protected in the event of upheaval. Stay engaged. Local and state protections matter. Back ballot measures and candidates who will uphold marriage equality in your state constitution. Final Thoughts Though it seems unlikely that Obergefell will be reversed in the immediate future, it would be unwise to become complacent or to assume it is beyond challenge. Now is the time to double-check your legal safety net, because the best time to protect your family is before the storm starts.
August 13, 2025
Landlord Representation
Federal Class Action Targets Common Add-On Charges in Virginia Leases: Pest and Community Fees Under Scrutiny
A federal class action lawsuit[1] is alleging that monthly pest fees and community fees are unlawful attempts to shift landlord obligations to tenants, in violation of the Virginia Residential Landlord and Tenant Act (VRLTA) and the Virginia Consumer Protection Act (VCPA). If the plaintiffs are successful, the case could trigger industry-wide consequences and result in substantial liability for property owners and managers who use similar fee structures. Initial Recommendations Evaluate all recurring fees, such as pest control, trash, amenity, and community fees to determine whether they relate to obligations that are legally the landlord’s responsibility under Virginia law (e.g., habitability and maintenance of common areas). Distinguish between charges for required services and those for optional or additional tenant benefits. Remove or recharacterize unlawful fees. Eliminate any separate fees that relate to non-waivable landlord duties. Where appropriate, incorporate the cost of pest control and common area maintenance into the base rent rather than charging them separately. Clearly define any remaining fees. Avoid using overly broad or ambiguous language such as “programs deemed necessary by ownership,” which may be interpreted as deceptive or misleading under consumer protection laws. Further Details and Legal Background Plaintiffs’ Allegations Plaintiffs allege that landlords cannot charge tenants for costs of pest control, trash disposal, or common area maintenance. Plaintiffs allege these duties are non-waivable landlord obligations under Virginia Code § 55.1-1220, and that the charging of pest control, trash disposal, and other common area maintenance fees are deceptive representations in violation of Virginia Code § 59.1-200(14). Legal Basis Virginia Residential Landlord and Tenant Act (VRLTA) Virginia Code § 55.1-1220(A): Requires landlords to maintain pest-free premises and clean, structurally safe common areas. These duties may not be waived through the lease. Virginia Consumer Protection Act (VCPA) Virginia Code § 59.1-200(14): Prohibits misrepresentation or deception in consumer transactions, including residential leases. The lawsuit claims tenants were misled into believing that payment of the pest and community fees was required to receive services already required under Virginia law. Analysis Importantly, Virginia Code § 55.1-1220 does not explicitly prohibit landlords from charging for pest control and trash disposal fees, if such fees are authorized under the lease agreement. Plaintiffs are, therefore, making allegations based on implication and a broad reading of Virginia Code § 55.1-1220. It is not clear how the court may rule on the plaintiffs’ allegations. Regardless, plaintiffs’ allegations have merit based upon landlords’ obligations as defined under Virginia Code § 55.1-1220. Potential Impact This lawsuit signals an aggressive new approach to enforcing landlord-tenant law under both the VRLTA and VCPA. This case could set precedent for whether bundling landlord obligations into fees is inherently deceptive under the VCPA and unlawful under the VRLTA. Further, a ruling in favor of plaintiffs could lead to a wave of similar class actions across Virginia and other states. Offit Kurman will continue to monitor the case and provide further recommendations once the court issues a ruling. [1] Valencia Rios v. Belvedere NRDE, LLC and Pegasus Residential, LLC (E.D. Va. No. 3:25-cv-474)
August 12, 2025
Estates and Trusts
Settling an Estate with Efficiency and Care — Guidance for the Personal Representative
When someone dies, the task of settling the person’s estate descends upon the personal representative. Being appointed a personal representative, or “executor,” is an honor that includes a broad range of responsibilities. This person must be part administrator, part accountant, and part diplomat! Depending on the complexity of the estate, the process can drag on for years, or the estate can be opened and closed the same day. A typical estate takes nine months to a year to close. Regardless of how complex the estate is, the personal representative may want to begin with a phone call to an estates and trusts attorney for guidance. The attorney can simply point the personal representative in the right direction during a single consultation. Or the attorney can assume some or all of the duties of the personal representative, making the process considerably less burdensome. The challenge for most people settling an estate is that they do this only once in their lives, and therefore have to learn on the job. Here is an overview of the steps involved. Secure the Home If a house is sitting vacant as a result of the death, it is important to protect the property and its contents. Any valuables should be removed and kept in a safe place. Windows and doors should be locked and the alarm set, if there is one. If other people have keys to the house, consider having the locks changed. Mail should be forwarded to the personal representative, and a trusted neighbor should be asked to keep an eye out for any packages or fliers left at the door. It is also important to pay any mortgage installments, condominium fees, utilities, or property taxes as they become due. If funds for these expenses are not immediately available, the personal representative can advance these costs and seek reimbursement from the estate when possible. Locate the Will To open the estate, you will need the original will—not a photocopy. Once located, the will should be filed with the Register of Wills, even if the decedent had no assets. (If there is no will, the person has died “intestate” and the assets will be distributed according to Maryland’s rules of intestacy.) Upon opening the estate, the personal representative will receive “Letters of Administration,” putting him or her in charge of the estate and its assets. A tax ID number can then be obtained, and an estate checking account opened. Notify Agencies of the Death Banks and brokerage houses should be notified of the death, as well as insurance, credit card, and utility companies, and credit-reporting agencies. If the person received Social Security or other government benefits, notify the agencies that provided them. Marshal the Assets It may be advisable to liquidate any securities and other investments to lock in the value as close to the date of death as possible. The proceeds from any liquidated accounts should be deposited in the estate checking account. Prepare an inventory of the estate assets, including cars and household items, as well as real estate (whether in Maryland or elsewhere), bank accounts, CDs, investment portfolios, and life insurance policies. The inventory must include the date-of-death value of each item and be filed with the Register of Wills. Determine whether any of the assets name a beneficiary or have a co-owner. Those that do may be “non-probate” assets, which will transfer to the beneficiary or co-owner directly and are not part of the probate estate. Run the Numbers Creditors of the deceased have six months to make claims against the estate, and if there are sufficient funds, these will need to be paid from the estate account. Estimate the amount of cash needed to pay the claims and any taxes, and, as necessary, arrange for any assets to be sold for distribution. Deal with Taxes A Form 1040 individual income tax return must be filed for the portion of the year the decedent was living. This return is due by April 15 of the following year, just like a standard personal tax return. If the estate includes bequests to individuals who are not close family members, Maryland's 10% inheritance tax will apply. Unless the will specifically states otherwise, this tax is generally payable by the beneficiary who receives the bequest. Estate taxes may also apply, depending on the total value of the estate. In Maryland, estates valued at more than $5 million may be subject to state estate tax of up to 16%. At the federal level, estates exceeding $13.99 million in value (as of 2025) may trigger federal estate tax obligations of up to 40%. In addition, during the course of estate administration, if the estate generates more than $600.00 in income—perhaps from interest or dividends—fiduciary income tax returns must be filed. This includes IRS Form 1041 for the federal return and Maryland Form 504 for the state return. Because estate and tax matters can be complex, enlisting the help of an accountant experienced in estate administration is often a wise decision. Make Distributions Once an accounting showing all estate activity has been filed and approved by the Register of Will, a 20-day waiting begins. If no objects are made to the accounting as filed, it will then be time to distribute the remaining assets to the beneficiaries. The personal representative might first ask each beneficiary to sign a document releasing the personal representative from any future liability in connection with the estate. Settling an estate is more than a legal obligation—it is a final act of care and respect for the person who has died. By carrying out their wishes with diligence, fairness, and thoughtfulness, the personal representative helps bring closure not just to the estate, but to the life it represents. Though the work can be complex and at times overwhelming, it is also a meaningful way to honor the departed and ensure that their final wishes are handled with integrity and grace.
August 11, 2025
Healthcare
FDA and FTC Legal Boundaries for Cosmetics
The FDA regulates the safety and labeling of cosmetics under the Federal Food, Drug, and Cosmetic Act (FDCA). It ensures products are not adulterated or misbranded and monitors whether certain claims transform a cosmetic into a “drug” under the law. On the other hand, the FTC oversees advertising practices, ensuring that cosmetic marketing is truthful, not misleading, and backed by reliable evidence. The FTC can take enforcement action against deceptive or unfair business practices in cosmetic advertising. This post covers why cosmetics companies must understand FDA and FTC roles. It also lets you know how to protect your brand from regulatory action. What is the FDA’s Role in Cosmetics Regulation? The U.S. Food and Drug Administration (FDA) plays an important role in overseeing the safety and labeling of cosmetic products sold in the United States. Under the Federal Food, Drug, and Cosmetic Act (FDCA), the FDA is responsible for ensuring that cosmetics are not adulterated or misbranded and that consumers are not misled by false or deceptive labeling. However, unlike drugs or certain medical devices, cosmetics do not require FDA pre-approval before they reach the market. This places a greater responsibility on manufacturers and distributors to ensure product compliance. Cosmetics, as defined by the FDA, are products intended to be applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance. This includes items like makeup, skin moisturizers, shampoos, deodorants, perfumes, and certain skin treatments. It’s important to note that if a product is marketed with claims that it treats or prevents disease or affects the structure or function of the body, it may be classified as a drug, even if it’s also a cosmetic. For example, a lotion marketed to moisturize the skin is a cosmetic, but one that claims to treat eczema would be regulated as a drug. Under FDA regulations, cosmetics must meet specific standards to be legally marketed. They must be safe for use under labeled or customary conditions, and their labeling must be truthful and not misleading. Cosmetic labels are required to include the name and address of the manufacturer or distributor, an accurate statement of the quantity of contents, and a complete listing of ingredients in descending order of predominance. The FDA also monitors for prohibited ingredients and contaminants that could pose a risk to consumer health. The FDA’s role is reactive rather than proactive. It typically steps in after products are already on the market if there are reports of adverse events, labeling violations, or safety concerns. One of the most significant distinctions in FDA law is the difference between cosmetics and drugs. Drugs are subject to much stricter regulations, including premarket approval, clinical trials, and adherence to Good Manufacturing Practices (GMP). A cosmetic becomes a drug if it makes claims to affect the structure or function of the body or to treat or prevent disease. What are FDA Legal Boundaries for Cosmetics? Cosmetics are products intended to be applied to the human body for cleansing, beautifying, promoting attractiveness, or altering appearance. These include personal care products such as skin moisturizers, fingernail polishes, perfumes, shampoos, and makeup. Under the Food, Drug, and Cosmetic Act (FD&C Act), the FDA classifies these products based on their intended use. If a product claims to affect the structure or function of the human body such as “treating acne,” “stimulating collagen production,” or “removing wrinkles”, it may be reclassified as a drug or even a medical device. Therefore, it is subject to far stricter regulations and requires FDA premarket approval. Cosmetic companies must stay within clear legal boundaries to avoid crossing into drug claims. While cosmetic products do not require FDA premarket approval, the FDA has authority over several aspects of cosmetic regulation. These include ensuring that products are not adulterated, meaning they contain harmful or contaminated substances, and that they are not misbranded, meaning their labeling is false, misleading, or lacking required information. The FDA does not evaluate the efficacy of cosmetics, unlike drugs, but it will take enforcement action if advertising claims are deceptive or if products are deceptively packaged. When cosmetic manufacturers make implied claims that a product has therapeutic benefits without proper substantiation, they risk violating both FDA and FTC legal boundaries. FDA Regulations for Cosmetic Ingredients and Safety Cosmetic manufacturers are responsible for ensuring that ingredients used in their products are safe for their intended use. Although there is no mandatory premarket approval for most cosmetic ingredients, color additives are an exception and must receive specific FDA approval before they can be used in cosmetic formulations. The FDA has banned or restricted certain harmful substances in cosmetics, such as mercury compounds and chlorofluorocarbons, to protect consumers from dangerous products. To comply with FDA law, cosmetic firms must implement internal quality control systems and conduct necessary safety testing. The agency does not require companies to submit clinical studies or other scientific data before marketing a product, but it does expect that adequate substantiation of safety exists behind the scenes. Any product found to be contaminated with harmful bacteria, improperly formulated, or otherwise unsafe may be considered adulterated under the FD&C Act, which could trigger regulatory action and even product recall. Cosmetic companies should also consider potential issues related to microbial contamination, especially in products like eye creams and hair dyes that may come into contact with sensitive areas of the body. FDA Requirements for Cosmetic Labeling and Claims The FDA enforces strict labeling requirements to inform consumers and prevent misleading or deceptive advertising claims. Cosmetic labels must include the product’s identity, the name and address of the manufacturer or distributor, the net quantity of contents, and a full list of ingredients in descending order of predominance. Usage instructions and required warnings must also be clearly visible and easy for consumers to understand. Products that are deceptively packaged or contain false or unsubstantiated claims may be considered misbranded. While cosmetics may make certain claims such as “moisturizes dry skin” or “adds shine to hair,” they must avoid language that implies a medical or therapeutic benefit unless the product has undergone drug-level scrutiny. For example, terms like “hypoallergenic” or “natural” may not have a standard FDA definition but should still be adequately substantiated to avoid potential FTC and FDA enforcement. Similarly, claims involving “anti-aging” or “reversing skin damage” must be carefully crafted to remain within the boundaries of cosmetic law. The FDA, in collaboration with the Federal Trade Commission, may pursue enforcement action against cosmetic manufacturers or distributors making deceptive or inadequately substantiated claims. FDA Adverse Event Reporting and Safety Monitoring Although reporting adverse events is not mandatory for cosmetic products, it is strongly encouraged under FDA guidelines. Serious adverse events, including those resulting in hospitalization, significant disability, or death, can be reported through the FDA’s Voluntary Cosmetic Registration Program (VCRP) or MedWatch system. These reports help the FDA monitor the safety of cosmetics on the market and take swift action when dangerous products emerge. Cosmetic manufacturers and distributors should develop internal systems to track and investigate consumer complaints. These systems can help identify trends in product safety issues and inform the need for corrective action, including product reformulation or voluntary recall. Adverse event data also helps the FDA evaluate whether certain products, ingredients, or packaging methods pose a risk to public health. Maintaining transparency with the FDA by reporting safety incidents not only demonstrates good faith but can also reduce the risk of severe enforcement action later on. FDA Enforcement Actions and Penalties for Non-Compliance If a cosmetic product is found to violate FDA regulations, the agency may initiate a range of enforcement actions. These include issuing warning letters, seizing products, seeking injunctions, or even pursuing criminal prosecution in extreme cases. While most FDA enforcement actions begin with informal discussions or warning letters, failure to take prompt corrective action can escalate the situation quickly. In some cases, the FDA may mandate or recommend a recall. Although most cosmetic recalls are initiated voluntarily by the manufacturer, the FDA has the authority to intervene if public safety is at risk. Legal issues associated with non-compliance can lead to product bans, reputational harm, or long-term scrutiny from regulators. FDA Guidelines for Cosmetic Product Recalls The FDA recommends that companies initiate a voluntary recall when they discover a product to be unsafe, mislabeled, or adulterated. Having a recall plan in place allows cosmetic manufacturers to respond quickly, communicate effectively with distributors, retailers, and consumers, and minimize harm. Recalls must be documented thoroughly and executed transparently to meet FDA expectations. The FDA may choose to monitor the recall process and evaluate its effectiveness. Public notices may be required to ensure that all affected consumers are informed. Proper record-keeping and traceability systems help cosmetic firms demonstrate compliance in the event of future inspections or audits. A prompt and transparent recall reduces legal risk and shows consumers that the brand prioritizes their safety. What is the FTC’s Role in Cosmetics Marketing and Advertising? The Federal Trade Commission (FTC) plays a central role in regulating advertising and marketing claims made by cosmetic companies in the United States. While the Food and Drug Administration (FDA) focuses on product safety, labeling, and classification, the FTC is the government agency responsible for ensuring that all advertising claims related to cosmetic products are truthful, not misleading, and adequately substantiated. The FTC’s jurisdiction covers everything from print and digital advertising to social media marketing, influencer endorsements, and product packaging that includes promotional language. The cosmetics industry must carefully observe both the FDA and FTC legal boundaries to prevent regulatory action and legal issues. Deceptive or misleading advertising is defined by the FTC as any marketing practice that misrepresents a product or omits important information in a way that is likely to mislead reasonable consumers. This includes both express claims and implied claims. For example, a claim that a skin moisturizer “eliminates wrinkles overnight” must be supported by solid scientific evidence; otherwise, the advertising is considered deceptive. The FTC also scrutinizes terms like “hypoallergenic,” “natural,” “organic,” or “dermatologist-recommended,” especially when such claims are used to suggest that a product is safer or more effective than it truly is. Without adequate substantiation, such claims can result in FTC enforcement action. Substantiation is a key requirement under FTC law. Cosmetic firms must be able to provide competent and reliable evidence to support any marketing claims, including clinical studies, consumer perception data, or other scientific backing. Claims made about consumer products, such as hair dyes or permanent waves, must not only reflect the intended use of the product but also align with consumer expectations based on the language used. The FTC emphasizes that advertising must inform consumers without misleading them, which means all claims must be truthful and not exaggerated. What Are the FTC Legal Boundaries for Cosmetics Marketing? Cosmetic companies must adhere to strict FTC guidelines that govern how products are marketed to consumers. Claims must be truthful, not misleading, and backed by evidence. Even statements that seem harmless, like “improves skin tone” or “revitalizes tired eyes,” can be considered deceptive if the advertiser cannot provide adequate substantiation. Implied claims, such as the suggestion that a product is “FDA approved” when it is not, are also prohibited. In fact, the use of government symbols, false certifications, or deceptive imagery that implies regulatory endorsement can result in swift enforcement action by the FTC. Endorsements and testimonials are another area of focus under FTC authority. When a cosmetic firm uses influencers, celebrities, or customer testimonials to promote their products, the FTC requires that any material connection between the endorser and the company be disclosed. This includes sponsored content, gifted products, paid partnerships, and affiliate links. If a social media influencer is compensated to promote a skin moisturizer or hair color, they must clearly state that the post is sponsored or that they received compensation. Failure to disclose these relationships can result in regulatory penalties for both the influencer and the brand. The FTC also requires that disclosures in advertising be “clear and conspicuous.” This means that disclaimers or qualifying information must be easy for consumers to see and understand, not hidden in fine print or buried at the bottom of a page. For example, if a cosmetic product has limited benefits that apply only under certain conditions, this must be stated clearly in the advertisement. The FTC monitors advertising claims through consumer complaints, marketplace surveillance, and collaboration with other agencies like the FDA. Companies that ignore these guidelines risk facing enforcement actions that could include fines, cease-and-desist orders, and public corrective advertising. Violating FTC advertising rules can lead to significant legal and financial consequences. Penalties may range from civil fines to injunctive relief, and in some cases, companies may be required to refund consumers or undergo long-term compliance monitoring. For small businesses and growing cosmetic firms, these penalties can be devastating. The FTC’s involvement in the cosmetics industry ensures that consumers are protected from dangerous products, misleading marketing, and deceptive advertising. It also holds cosmetic manufacturers accountable for maintaining ethical marketing practices and adequately substantiating every claim they make. How Do FDA and FTC Regulations for Cosmetics Differ? The FDA and the FTC are two government agencies that regulate cosmetic products, but their responsibilities are distinct and complementary. The FDA (Food and Drug Administration) focuses primarily on product safety, labeling accuracy, and ensuring that cosmetics are not adulterated or misbranded under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Its role centers around how products are formulated, labeled, and packaged, and whether they comply with safety standards, particularly regarding color additives, banned substances, and proper disclosure of ingredients. In contrast, the FTC (Federal Trade Commission) regulates the advertising and marketing claims made by cosmetic companies under its authority to prevent deceptive or misleading business practices. The FTC’s jurisdiction extends to all forms of advertising, including digital content, influencer partnerships, endorsements, product packaging, and traditional media. The agency ensures that cosmetic firms do not make false, unsubstantiated, or exaggerated claims about product performance, such as suggesting a cosmetic can cure, treat, or prevent a medical condition. These different approaches significantly impact how cosmetic businesses operate. While the FDA might inspect a product for microbial contamination, inadequate labeling, or banned ingredients, the FTC will scrutinize whether the product’s marketing is backed by adequate substantiation, particularly when it includes terms like “natural,” “clinically proven,” or “hypoallergenic.” For example, a brand selling skin moisturizers might pass an FDA inspection for safety but still face FTC enforcement if its ad falsely claims that the product reverses aging without credible clinical evidence. Despite their different focus areas, FDA and FTC legal boundaries often intersect, especially when cosmetic claims stray into drug territory. If a company markets a cosmetic with language like “treats acne” or “heals eczema,” the FDA may classify that product as a drug, subjecting it to far more stringent regulations, including premarket approval. At the same time, the FTC could step in if those claims lack scientific backing, even if they fall short of FDA-defined drug claims. In such cases, both agencies may pursue regulatory action, making it critical for businesses to stay alert to overlapping rules. To remain compliant, cosmetic firms should build strong internal systems to ensure their product formulations, labels, packaging, and advertising meet the expectations of both agencies. Working with regulatory experts who understand the nuanced requirements of the FDA and FTC, like the experts at Cohen Healthcare Law Group, can help avoid costly missteps. What Are the Legal Risks of Violating FDA and FTC Rules? Violating FDA and FTC regulations poses serious legal risks for cosmetic companies. The FDA may issue warning letters to companies whose products are considered misbranded or adulterated, demanding immediate corrective action. In more serious cases, the FDA can escalate enforcement through product seizures, injunctions, import bans, or even criminal prosecution, especially when companies continue to market dangerous products or ignore FDA orders. Meanwhile, the FTC can impose civil penalties, cease-and-desist orders, and require companies to issue corrective advertising when marketing claims are found to be deceptive or misleading. These actions often come with costly fines and force businesses to halt sales until compliance is achieved. For example, if a firm advertises a hair dye as “clinically proven to regrow hair” without substantiating the claim, the FTC can step in to stop the ad campaign and demand refunds to consumers. Beyond regulatory fines, companies may be forced into expensive product recalls, especially if labeling errors or false claims affect large volumes of product already in circulation. A recall can erode consumer trust, lead to negative media attention, and damage a brand’s long-term reputation. Even worse, legal actions from these agencies can lead to lengthy investigations, mounting legal fees, and lost revenue from paused operations or delisted products. Non-compliance doesn’t only affect large brands. Small businesses in the cosmetics industry are equally at risk and may be less prepared to absorb the financial fallout of enforcement actions. This makes proactive compliance a key business strategy, ensuring that every product launched is legally sound from formulation to final advertisement. How Can Businesses Ensure Compliance with FDA and FTC Regulations? To stay compliant, cosmetic companies must first ensure they understand and follow all applicable FDA and FTC requirements. This includes knowing the difference between a cosmetic and a drug under FDA law, using only FDA-approved color additives, and avoiding ingredients known to be banned or restricted. Labels must clearly identify the product, include the required information, and avoid misleading claims that could make a product appear FDA approved when it is not. Businesses must also align their marketing strategies with FTC standards, which require that all advertising claims be truthful, non-deceptive, and adequately substantiated. Before using terms like “organic,” “non-toxic,” or “clinically tested,” companies should gather and document credible evidence, such as lab testing, clinical studies, or expert evaluations. Testimonials and influencer partnerships must follow FTC rules for disclosure, particularly when financial or material relationships are involved. One of the most effective ways to ensure compliance is to work closely with experienced healthcare or regulatory attorneys. Legal professionals can review claims, labeling, website content, and promotional campaigns for red flags, helping businesses adjust messaging before a regulator intervenes. In addition, companies should keep detailed documentation of ingredient sourcing, safety testing, and marketing claim substantiation so they are prepared in the event of an audit, product recall, or regulatory complaint. By creating an internal compliance process that covers both product safety and advertising practices, cosmetic manufacturers can operate confidently within the legal boundaries set by both the FDA and FTC. The stakes are high, but with the right systems in place, businesses can protect their brand, avoid costly penalties, and earn consumer trust in an increasingly competitive market. Want to Stay Compliant with FDA & FTC Rules? For the cosmetics industry, compliance with FDA and FTC regulations is essential. The FDA ensures that your cosmetic products are safe, properly labeled, and not adulterated or misbranded. Meanwhile, the FTC holds you accountable for truthful, non-deceptive advertising and marketing practices. Failing to comply with either agency’s standards can result in serious consequences, including product recalls, warning letters, financial penalties, lawsuits, and long-term damage to your brand reputation. That’s why it’s important to stay informed, proactive, and legally prepared as you grow your cosmetic business. FAQs Here are answers to common questions about cosmetic regulations in the U.S. When Can the FDA Take Legal Action Against a Cosmetic on the Market? The FDA can take legal action if a cosmetic is adulterated (unsafe or contaminated) or misbranded (improperly labeled or misleading). This includes actions like warning letters, seizures, injunctions, and even criminal prosecution. What Are the Two Most Important Laws Pertaining to Cosmetic Sales in the US? The primary laws are the Federal Food, Drug, and Cosmetic Act (FDCA) and the Fair Packaging and Labeling Act (FPLA). These govern product safety, labeling, and truthful marketing. Can You Sell Cosmetics Without FDA Approval? Yes, cosmetics do not require FDA premarket approval before being sold, except for color additives, which must be FDA-approved for their intended use. What Claims Can Cosmetics Companies Legally Make? Cosmetic companies can make claims related to enhancing appearance (like moisturizing or smoothing) but cannot claim to treat or prevent diseases or affect the structure or function of the body without being classified as a drug.
August 11, 2025
Labor and Employment
New DOJ Memo Addresses Legality of DEI Programs for Federal Funding Recipients
On July 30, 2025, the Department of Justice released a memo from Attorney General Pam Bondi offering guidance to federal agencies and recipients of federal funding regarding practices that the administration views as potentially unlawful under federal antidiscrimination laws. While the memo focuses heavily on institutions of higher education, its implications extend to all federal funding recipients, federal contractors, and employers subject to Title VII. The memo outlines the administration’s interpretation of federal law as it applies to diversity, equity, and inclusion (DEI) initiatives and similar programs. It provides examples of practices the DOJ considers unlawful or legally questionable, as well as "best practices" intended to help organizations avoid liability. Key Takeaways Applicability Beyond Higher Education: Although many examples concern colleges and universities, the guidance expressly encourages all entities subject to federal antidiscrimination laws, including public and private employers, state and local governments, and contractors, to review and evaluate their DEI programs. DOJ’s Interpretations Are Not Binding Law: The memo reflects the DOJ’s interpretation of existing law, not a change in the law itself. Courts remain the final arbiters of what federal statutes mean, and state laws may impose different or additional requirements, especially in areas such as transgender rights, where the administration’s views may conflict with both state law and judicial precedent. Examples of Practices the DOJ Views as Unlawful or Problematic Race-Based Scholarships or Opportunities: Programs that limit access to scholarships, internships, or leadership initiatives based on race (e.g., a “Black Excellence Scholarship”) violate federal law unless they meet the very high bar for race-conscious programs. Race-Exclusive Facilities or Resources: DEI initiatives that designate certain physical spaces (e.g., “BIPOC-only lounges”) or create identity-based access restrictions may amount to unlawful segregation or exclusion, even if intended to foster inclusion. Segregated Training or Affinity Groups: Programs that separate participants based on race (e.g., mandatory DEI sessions with race-exclusive breakouts) risk violating civil rights laws. Voluntary, open-to-all professional support networks may be permissible. Diverse Slate Hiring Requirements: Mandating racial or demographic composition in interview pools (e.g., requiring a minimum number of minority candidates per hiring slate) may violate the law if used to exclude otherwise qualified individuals based on race. Race- or Sex-Based Contracting Preferences: Automatically favoring minority- or women-owned businesses in procurement decisions, without narrowly tailoring those preferences to a compelling government interest, raises legal concerns. Note: The DOJ flags this area as particularly sensitive given that many entities, including government contractors, are required to establish utilization goals for disadvantaged businesses. The legality of these long-standing programs may now be in flux. Proxies for Race or Sex Consideration: Cultural Competence or “Lived Experience” Requirements: When tied to race or ethnicity, such criteria may unlawfully advantage candidates based on protected characteristics Diversity Statements or “Obstacle” Essays: Requiring narratives that implicitly reward racial or gender identity may function as indirect proxies for discrimination The memo sharply narrows the permissible interpretation of the Supreme Court’s language in Students for Fair Admissions v. Harvard, particularly Chief Justice Roberts’ explicit statement that applicants may discuss how race shaped their experiences, provided race itself is not the basis for decisions. Recommended “Best Practices” To reduce legal risk, the DOJ encourages organizations to: Eliminate Demographic-Driven Goals: Avoid designing policies or using facially neutral criteria (e.g., “first-generation student” or “underserved zip code”) to achieve demographic outcomes tied to protected characteristics Justify Criteria with Legitimate, Non-Discriminatory Rationales: Document how selection criteria are related to objective performance or institutional needs — not race, sex, or other protected traits Evaluate Potential Proxy Effects: Before implementing race-neutral policies, assess whether they function in practice as proxies for race, sex, or other protected statuses Abandon Diversity Quotas: Avoid policies that require representation of specific demographic groups in candidate pools, committees, or final hiring selections Include and Enforce Nondiscrimination Clauses in Contracts: Require third parties receiving federal funds to comply with nondiscrimination obligations. Monitor compliance and terminate funding where violations occur. Note on Scope of Coverage The DOJ memo applies to recipients of federal financial assistance, which includes grants, loans, subsidies, and insurance, not federal procurement contracts. However, many principles may be relevant to federal contractors, particularly where compliance with Title VII or similar statutes is at issue.
August 8, 2025
Intellectual Property
Future-Proofing Your Brand During Expansion
Expanding a brand into a new category can be an exciting time. It can also be one of the riskiest moves a brand can make. Branding is more than logos or ad campaigns. It’s about identity, voice, values, and the emotional connection with your audience. Whether it's a fashion house entering beauty, a beverage company exploring wellness, or a tech firm launching a novel product, the potential for growth is enormous. But with that opportunity comes risk. When managed well, brand expansion reinforces that connection, but when rushed or misaligned, it weakens the trust that took years to build. Why Future Proofing Matters from Day One Often, brands treat category expansion like a standalone marketing campaign. They focus on quick wins, media buzz, short-term sales, or a different position in shelf space, which, without a strategic foundation, can backfire. Every product launch, brand partnership, or new line sends a message to consumers about what your brand stands for. That means any missteps risk undermining that story. Future proofing begins by asking tough but essential questions: Does this new product offering align with our brand’s culture? Will our core messaging still align as we scale or expand into new regions or categories? Define the Relationship with the Parent Brand An often undervalued aspect of expansion is the structure that connects the dots on how new offerings relate to the master brand. Will the new product be a sub-brand, an extension, or something distinct and possibly even unrelated? Consider Apple’s ecosystem: iPhone, iPad, Apple Watch, AirPods. Each product serves a unique function, yet they all come together and reinforce the parent brand’s identity of innovation and integration. That clarity builds customer trust and makes each launch feel like a natural extension of what consumers already believe about Apple. In-House vs. Licensed: A Strategic Decision Deciding to build a new category in-house or license it to a third party is important and has significant financial implications. Licensing can offer speed as well as immediate category expertise. Additionally, licensees will generally have established distribution channels in their product category. However, licensing carries the risk of inconsistent execution and diminished brand control. In contrast, in-house development ensures alignment but can stretch internal resources and delay time-to-market. Neither option is inherently better; it depends on your long-term goals. Some brands start with licensing, then bring successful categories in-house to better integrate them into the brand’s DNA. Choose the approach that supports authenticity, quality, and growth over time. Be realistic about what it takes to launch a new product category from product development through sales and distribution. Going Global? Think Local Launching into new regions multiplies complexity, particularly when expanding internationally. What resonates with customers in North America might fall flat in Asia without cultural and regional nuances. A one-size-fits-all global campaign can seem tone deaf. Moreover, international regulations pertaining to product categories can differ substantially, and fluctuating tariffs and trade treaties may also impact a company’s ability to be successful in a country or region. Strong brands can adapt for regional differences in messaging, image, tone, and packaging, etc., while still expressing a consistent global identity. Nevertheless, brands must still learn the local market and its customs, and understand how to navigate and comply with local regulations. Beyond the Launch: The Core of a Future-Proof Brand To future-proof your brand, you need to think beyond launch day. A brand isn’t defined by one product, campaign, or social media moment. It’s how your customers experience and perceive you over time. Strong brands continuously learn from their customers, observing shifts in expectations, sentiment, and values. Gen Z, for example, views itself as a stakeholder in the brands it supports. They expect companies to live up to their stated values, and they take notice and speak out on TikTok when those values ring hollow. Authenticity is key. Internal Culture Is Brand Culture Your external brand reflects your internal culture. When your employees, from C-suite to frontline workers, understand and live the brand’s values, it shows in every customer interaction. Future-proofing your brand requires embedding that alignment throughout your organization. Your brand is reflected in the way products are designed and services are delivered. Everyone should feel a sense of ownership in the brand story and understand how their role contributes to it. Every touchpoint, from social media posts, customer service exchanges, product packaging, and speaking engagements, is a chance to reinforce (or undermine) your brand. Nourish the Brand Ongoing thought leadership helps keep your brand visible, relevant, and aligned with your customers' needs. Great brands often own a point of view in their industry, publishing insights or setting trends that reinforce their authority. Measure what works through perception studies, engagement metrics, and customer feedback, and adapt accordingly. The market will change. Customers will evolve. Competitors will disrupt. Your logo may stay the same or change, but the context in which it operates never does. The launch is just the beginning. Your brand's success depends on how well it fits into a broader, evolving dialogue. Future proofing is about preparing your brand to meet what comes next.
August 8, 2025
Healthcare
What Are FDA Warning Letters and How Do They Impact You?
FDA Warning Letters are formal notifications issued by the U.S. Food and Drug Administration (FDA), to individuals or businesses that have violated FDA regulations. These letters typically identify specific violations such as misbranding, marketing unapproved products, improper manufacturing practices, or deceptive claims, and provide the recipient a limited time to respond and correct the issue. In this post, we’ll break down what FDA warning letters are and why they matter. We will also let you know common reasons companies receive FDA letters and how best to respond to them. What is an FDA Warning Letter? An FDA Warning Letter is an official notification sent by the U.S. Food and Drug Administration to firms or individuals found to be in significant violation of federal law. These letters are considered the agency’s principal means of advisory correspondence, used when FDA investigators determine that a company has violated the Federal Food, Drug, and Cosmetic Act (FD&C Act) or related implementing regulations. The purpose of the letter is to inform the recipient of the violations in sufficient detail and to request prompt corrective action to bring the business into compliance. FDA warning letters are different from other types of FDA communications. These include recalls, inspections, and form citations, such as Form 483. Unlike recalls, which are typically voluntary actions initiated by companies to remove potentially harmful products, a warning letter is a regulatory action meant to prompt compliance before more severe steps. These could include legal action, seizures, or injunctions. Unlike routine inspections or follow-up communications, a warning letter reflects the FDA’s belief that the violation is of regulatory significance and has not been adequately corrected. The legal implications of receiving an FDA warning letter are serious. Although the letter itself is not a final agency action and does not immediately trigger penalties, it clearly states that failure to promptly correct the violations could lead to further enforcement action. These actions may include denying the approval of new products, import detentions, or even prosecution in certain situations. Firms are typically given 15 business days to submit a written response detailing the steps they have taken or will take to correct the violations, and the FDA may issue a close-out letter only after determining that the corrective action has been completed to its satisfaction. Common Reasons for FDA Warning Letters FDA warning letters are issued across many sectors of the regulated industry, including food, dietary supplements, cosmetics, pharmaceuticals, and medical devices. One of the most common reasons for a warning letter is manufacturing violations, particularly a failure to comply with Good Manufacturing Practices (GMP). These lapses may include poor recordkeeping, inadequate sanitation, or faulty equipment maintenance, all of which pose a risk to public health and violate established regulations. Another widespread issue involves labeling and advertising violations. Companies may make unauthorized claims about their products, such as suggesting they can treat or cure diseases. Thus, the regulatory status of a food or cosmetic product can shift to that of an unapproved drug. Marketing a product as something it is not, or failing to include required information on a label, can result in a finding that the firm is violating federal law. The FDA also issues warning letters in response to failures in safety protocols, such as inadequate procedures during clinical trials or improper handling of adverse event reports. These types of violations jeopardize patient safety and show disregard for regulatory requirements. Data integrity issues have also become a growing concern. Firms must ensure that all data submitted to the FDA is complete, accurate, and verifiable. Any effort to falsify, obscure, or omit critical information, especially regarding product testing or quality control, will trigger swift FDA scrutiny. Lastly, unauthorized marketing of products, such as selling unapproved drugs, misbranded supplements, or promoting uses not cleared by the FDA, is a significant red flag. The FDA considers such activities a violation of law and will issue a warning letter if the agency believes that such marketing puts consumers at risk or misleads the public. How the FDA Issues Warning Letters The process begins with an FDA inspection or investigation of a firm’s facilities, website, products, or promotional materials. These inspections may be routine, triggered by consumer complaints, or follow-ups to previous violations. During an inspection, FDA investigators collect evidence and document potential violations. If they find issues of regulatory significance, they typically issue a Form 483 listing their observations. After the inspection, the FDA carefully reviews the findings to determine whether a warning letter is warranted. The decision depends on several criteria, including the risk posed to consumers, whether the violations have been previously addressed, and if the company has voluntarily complied in the past. If the agency believes that the violations remain unresolved or serious enough to require a formal response, it will issue a warning letter. The warning letter is typically sent by overnight delivery to the highest known official at the company. The timeline from inspection to issuance of a warning letter can vary, but, generally, it occurs within a few weeks to months after the inspection, depending on the complexity of the issues and the FDA’s internal review process. Once the letter is received, the firm must submit a written response, typically within 15 business days, explaining how it will promptly resolve the issues discussed. The agency may initiate subsequent interaction, including regulatory or enforcement action, if the firm fails to respond adequately. FDA Warning Letters are publicly posted on the FDA’s website, making them visible not only to consumers and the media but also to other regulatory bodies and potential business partners. The consequences of receiving a letter can ripple across the business, affecting everything from partnerships to product launches. What Happens If You Ignore an FDA Warning Letter? Ignoring an FDA warning letter is one of the most dangerous missteps a company can make. While the letter itself is not an immediate enforcement action, it is a critical regulatory warning and a clear signal that the agency has identified violations of federal law and expects prompt corrective action. When a firm chooses not to respond or fails to make adequate corrections, the situation can escalate quickly and severely. In the worst-case scenario, the FDA may pursue legal action against the company. This could include civil or criminal penalties, including injunctions that shut down operations or seizures of products that are considered misbranded, adulterated, or otherwise noncompliant. The agency can also impose significant fines, pursue prosecutions, and even refer the case to the Department of Justice. Another major consequence of ignoring an FDA warning letter is the potential loss of business licenses, certifications, or approvals. For companies operating in highly regulated areas like clinical trials, medical devices, or drug manufacturing, failure to comply can lead to the revocation of regulatory status and product approvals. This means affected firms can no longer legally market or sell their products in the United States, cutting off vital revenue streams and destroying entire business models. Beyond regulatory and legal consequences, the impact on consumer trust and brand reputation can be devastating. FDA warning letters are made public, and once news of noncompliance spreads, consumers often lose confidence in the brand. Competitors may capitalize on the fallout, media outlets may amplify the controversy, and partnerships or investor relationships may begin to deteriorate. What to Do Immediately After Receiving an FDA Warning Letter Receiving an FDA Warning Letter can be alarming, but the most important thing to remember is that it’s not the end. Instead, interpret it as a warning that the FDA suspects your firm of breaking federal law, and they anticipate prompt corrective action. Here is what you should do: Read the Letter Carefully: Every FDA warning letter includes sufficient detail about the violations observed. The letter provides references to the violated laws, regulations, or guidance documents. Take note of specific claims, products, or practices the FDA has flagged, and pay close attention to the date of issuance and the deadline by which a written response must be submitted. Consult Internal Teams: Notify your quality assurance, regulatory, and legal departments. These teams will need to determine the scope of the issues discussed and begin gathering any records, reports, or data that could serve as evidence in addressing the FDA’s concerns. This is especially critical in industries like food, clinical trials, and drug manufacturing, where regulated industry standards are strict and noncompliance can result in legal action or enforcement action. Consult a Healthcare Lawyer: While your internal staff can help interpret the letter and collect internal documentation, a qualified FDA attorney understands the nuances of regulatory significance, can anticipate how the agency may react to your response, and can help you avoid missteps that might escalate into injunctions, product seizures, or other actions. A lawyer such as the attorneys at Cohen Healthcare Law Group will also help you draft a legally sound and strategic written response that aligns with FDA expectations and shows your willingness to voluntarily comply. Assess the Severity: Are the violations procedural or labeling-related, or do they involve unapproved drugs, data integrity, or unsafe practices? The risk level associated with the violations will influence how quickly and extensively you must act. In certain situations, the findings may relate to prior violations or indicate patterns that the FDA considers serious enough to warrant close scrutiny and subsequent interaction. Gather Relevant Documentation: Such documentation may include manufacturing logs, labeling files, marketing content, safety reports, or correspondence related to clinical trials or product approvals. The goal is to show that either the issue has been adequately corrected or that you have a clear plan to bring operations into full compliance. Develop a Response Plan: This plan should outline each corrective action you will take to resolve the issues discussed in the letter. The plan should also assign accountability within your team and include target dates for implementation. The FDA expects firms to go beyond general promises and demonstrate concrete actions supported by documentation. Prepare a Formal Written Response: This letter must be clear, factual, and free of emotional or defensive language. Reference the specific violations the FDA has cited and explain how your firm is addressing each one. Provide evidence where possible. The tone should convey that your company takes the warning seriously and is committed to promptly correcting any deficiencies. Implement Corrective Actions Promptly: The FDA expects action, not just intention. Delays in taking action, or failure to act at all, could lead to other actions like re-inspections, further letters, or escalated regulatory enforcement. If your response is accepted and the agency is satisfied with your efforts, you may eventually receive a close-out letter, confirming the matter has been resolved. Keep Open Communication with the FDA: If the agency requests additional information or clarification, respond quickly and with professionalism. Your willingness to cooperate can influence how the FDA handles future interactions and inspections. Continuously monitor compliance: Many firms tend to view a warning letter as an isolated incident rather than a systemic problem. Create internal audit systems, train your staff, and regularly review your adherence to regulations to avoid future violations. A solid compliance culture is the best defense against repeat offenses and the regulatory fallout that can follow. How to Stay Compliant and Prevent FDA Warning Letters? The best way to avoid receiving an FDA warning letter is by proactively building a culture of compliance. The FDA expects companies to not only correct violations after they occur but also to take preventative steps that ensure their operations, documentation, and products meet the requirements of federal law from the start. One of the most effective ways to do this is by implementing a robust Quality Management System (QMS). A well-structured QMS serves as a framework for ensuring product safety, consistency, and regulatory alignment, making it far less likely that FDA investigators will uncover violations during inspections. In addition to implementing a QMS, conducting regular internal audits and inspections is essential. These internal reviews help firms detect potential issues before the FDA does, offering the opportunity to resolve problems proactively and promptly correct any gaps in processes. Internal audits also provide valuable documentation that can serve as evidence of your commitment to voluntarily comply with all applicable laws and regulations. Routine audits also prepare your team for actual FDA inspections, reducing the chance of surprises that may lead to a warning letter. Employee training and documentation are equally important. Most violations cited in FDA warning letters involve human error, poor practices, or incomplete records. Every team member must be well-versed in FDA requirements, including the cosmetic act, clinical trial regulations, labeling rules, and other implementing regulations. Consistent training and written instructions ensure that employees are aware of their responsibilities, know how to conduct themselves during inspections, and can follow through with proper documentation practices. This type of preparation goes a long way in minimizing regulatory significance when errors do occur. Finally, staying compliant means staying updated with FDA regulations and guidance. The FDA frequently releases new advisory statements, clarifications, and updates that affect how companies must operate. Changes in how unapproved drugs, food products, or supplements are regulated can shift a product’s regulatory status overnight. Businesses that fail to track these updates may unintentionally find themselves in violation, leading to letters, follow-up inspections, or even enforcement actions. Therefore, designate a compliance officer or legal advisor to monitor changes in FDA policy and ensure your systems and products are always in alignment with current regulations. Received an FDA Warning Letter? Ensure Your Compliance FDA warning letters are clear signs that the FDA believes your company has violated federal law and that immediate, prompt corrective action is necessary. These letters often follow inspections or investigations and detail violations related to manufacturing practices, labeling, marketing of unapproved products, or failure to meet safety and documentation standards. While the letter itself doesn’t impose penalties, ignoring it can lead to severe consequences, including legal action, product seizures, injunctions, and lasting damage to your company’s regulatory status and reputation. The right response to an FDA warning letter involves reviewing the letter in full, gathering the necessary documentation, developing a corrective strategy, and submitting a timely and detailed written response. Just as important is preventing future issues by investing in a strong quality management system, conducting internal audits, providing ongoing employee training, and staying current with evolving FDA regulations and guidance. FAQs Below are answers to some of the most common questions businesses ask after receiving an FDA warning letter: How to Respond to an FDA Warning Letter? You must submit a formal written response within 15 business days, clearly addressing each cited violation and outlining specific corrective actions. The FDA expects both a detailed plan and evidence of implementation. What Is the Difference Between a 483 and a Warning Letter? An FDA 483 is an inspectional observation issued at the end of an inspection, while a warning letter is a more serious follow-up indicating that the FDA believes violations have regulatory significance and must be promptly corrected. Are FDA 483 Letters Public? FDA 483s are not automatically made public, but they can be accessed through Freedom of Information Act (FOIA) requests or published voluntarily in some cases. Are Responses to FDA Warning Letters Public? Yes, responses to FDA warning letters may be posted on the FDA’s website or released through FOIA requests, especially if the case is closed with a “close-out letter.”
August 8, 2025
Estates and Trusts
Major Estate Tax Changes Under the One Big Beautiful Bill Act
The One Big Beautiful Bill Act (OBBBA), signed into law on July 4, 2025, is a sweeping piece of legislation spanning nearly 1,000 pages. It includes significant changes to federal estate and income tax laws that will affect estate planning. Here’s an overview of a few key provisions in OBBBA and some strategic estate planning opportunities that it provides. Estate and Gift Tax Exclusion Increased Effective January 1, 2026, the federal estate and gift tax exclusion increases to $15 million per individual (or $30 million per married couple), with future adjustments for inflation. Although the increased exclusion was made “permanent” under the Act, it may still be changed or repealed by a future Congress or administration. High-net-worth clients should take full advantage of what may be a limited window for significant planning options. Spousal Lifetime Access Trusts (SLATs) and Grantor Retained Annuity Trusts (GRATs) are excellent options for front-loading an estate plan while still allowing the client or spouse access to assets. Individuals who have already utilized all or a portion of their current exclusions should consider “topping off” their current estate plans with additional gifts. While the increase in the federal exclusion amount provides substantial federal tax relief, state-level estate and inheritance taxes still apply, in many jurisdictions: 12 states (Connecticut, Hawaii, Illinois, Maine, Maryland, Massachusetts, Minnesota, New York, Oregon, Rhode Island, Vermont, Washington) and the District of Columbia continue to impose an estate tax Six states (Iowa, Kentucky, Maryland, Nebraska, New Jersey, Pennsylvania) impose an inheritance tax Connecticut is the only state that also imposes a gift tax New York does not have a gift tax, but adds back gifts made within three years of death to the taxable estate With proper planning, assets can still be transferred free of both federal and state-level transfer taxes, but state-specific rules must be carefully navigated. Spousal Lifetime Access Trusts (SLATs), Dynasty Trusts, and sales to intentionally defective grantor trusts offer excellent opportunities to both leverage and utilize the $15 million federal gift tax exclusion while removing those assets from a state estate tax regime. New York’s Estate Tax “Cliff” New York’s estate tax has a particularly harsh feature known as the “estate tax cliff.” This means that estates just slightly over the exclusion amount may lose the exclusion entirely and owe significant tax. For example, in 2025: A New York taxable estate of $7,160,000 will owe no estate tax A New York estate of $7,161,000 will owe $2,863 in tax A New York estate of $7,518,000 will owe $707,648 This makes planning for residents of New York and similarly situated states especially important. New York State residents, and even non-resident individuals with substantial New York situs property, should consider making immediate and significant gifts designed to lower their New York taxable estates below the cliff. If they survive three years after the gift, the gifted property will be excluded from their New York taxable estate. Generation-Skipping Transfer (GST) Tax Exemption The federal GST tax exemption also increases to $15 million per individual beginning January 1, 2026. This is particularly relevant for gifts or bequests made to “skip persons” (such as grandchildren) or to trusts subject to GST tax. Despite the increase, careful planning is still needed to make full use of this exemption. Unlike the federal estate and gift tax exclusion, the increased GST tax exemption is not “portable” – meaning that unless both spouses’ GST exemptions are used during life, they may be forfeited at the first death. And like the federal estate and gift tax exclusion, the increased GST tax exemption is also subject to a potential repeal if the political winds change. For clients and their families focused on multi-generational planning, now is the time to “use it or lose it” by fully sheltering appreciating assets from the generation skipping tax in an irrevocable trust. Careful allocation of exemption is the key to maximizing tax efficiency and wealth for future generations. SALT Deduction Cap Raised — But with Limits Starting in 2025, the cap on deductions for state and local taxes (SALT) increases from $10,000 to $40,000. This is especially beneficial for residents in high-tax states. However, the increased cap phases out for high-income earners: For those with modified adjusted gross income (MAGI) between $500,000 and $600,000, the cap is reduced by 30% of the excess MAGI The deduction is completely phased out for taxpayers with MAGI of $600,000 or more Unless extended, the cap will revert to $10,000 in 2030. Clients living in high-tax states should consider “stacking” multiple non-grantor trusts. Since each trust is treated as a separate taxpayer under the Internal Revenue Code, carefully drafted multiple trusts can potentially reallocate MAGI and shelter thousands of dollars in SALT deductions that could not otherwise be taken on an individual’s income tax return. Changes to Charitable Giving Rules OBBBA introduces new benefits and limitations for charitable giving: The 60% limitation for cash contributions to qualified charities is not “permanent” Standard deduction filers can now take an additional $1,000 charitable deduction ($2,000 for joint filers) Itemizers are subject to a new 0.5% floor, meaning charitable deductions are only allowed to the extent that total contributions exceed 0.5% of adjusted gross income (AGI) before losses To maximize deductibility, the new 0.5% floor encourages consolidating charitable giving in a single tax year. For high-net-worth individuals, this is the perfect opportunity to fund or expand a private foundation. Donor-advised funds may also provide an option for maximizing charitable giving in a single year while providing flexibility in the choice of charities and the timing of distributions. Final Thoughts The OBBBA marks a significant shift in the tax landscape for estate planning. While some changes provide enhanced opportunities for wealth transfer and charitable giving, others introduce complexity and planning pitfalls — especially at the state level.
August 7, 2025
Intellectual Property
Voice Actors Clear Early Legal Hurdle in AI Cloning Suit
Voice actors received a rare, if incomplete, victory against alleged AI infringers in a recent opinion from an SDNY judge in Lehrman v. Lovo, Inc. Voice actors Paul Lehrman and Linnea Sage filed an action against AI voiceover company Lovo, alleging the company used artificial intelligence to synthesize and sell unauthorized "clones" of their voices. Plaintiffs discovered their voices being used in YouTube videos and podcasts after they had been hired through the freelancing app, Fiverr, for what they believed were limited voice recording projects used for research purposes. The result is a case of first impression regarding AI voice cloning tech, asserting claims under New York civil rights and consumer protection laws, the Lanham Act, the Copyright Act, and various common law theories, including breach of contract, fraud, conversion, unjust enrichment, and unfair competition. Judge J. Paul Oetken issued a mixed ruling on Lovo's motion to dismiss, concluding that "for the most part, Plaintiffs have not stated cognizable claims under federal trademark and copyright law." The court explained that what plaintiffs sought was essentially "copyright protection for their voices" as abstract concepts rather than specific expressions, and that copyright "must concern the expression of ideas, not the ideas themselves." However, the court did allow the plaintiffs’ breach of contract and right of publicity claims to proceed, finding that communications through Fiverr and the platform's terms of service supported their allegations that the voice recordings were used beyond the agreed scope. The court also moved claims under New York Civil Rights Law Sections 50 and 51 forward, stating that these state laws are "tailored to balance the unique interests at stake" in voice misappropriation cases. While the ruling represents a partial victory for the voice actors, it highlights significant gaps in federal intellectual property protections for AI-generated content and voice cloning technology. The court's decision suggests that voice actors and similar plaintiffs may find more success pursuing state law remedies for unauthorized AI voice cloning rather than relying on federal copyright protections.
August 6, 2025
Estates and Trusts
Estate Planning for Musicians and Protecting Your Legacy Off the Stage
For musicians, estate planning is not just about deciding who inherits guitar collections or song royalties. It is about protecting your artistic legacy, ensuring your intellectual property is handled according to your wishes, and providing clarity for loved ones who may be unfamiliar with the nuances of the music industry. Unlike a typical estate plan, musicians face unique considerations, especially when it comes to rights management, royalties, and long-term protection of their creative works. Whether you are a seasoned performer or an up-and-coming artist, here are essential estate planning steps every musician should take. Catalog and Protect Your Intellectual Property Your songs, recordings, compositions, and even unreleased material are valuable assets. The first step is creating a comprehensive inventory of your published works, unreleased recordings or demos, copyright registrations, licensing agreements, and publishing contracts. Ensure these assets are clearly documented in your estate plan, which means if you have a revocable trust in place, these assets must be “assigned” to that trust to avoid probate. You should also provide instructions to your trustee or executor on how these assets should be managed, distributed, and monetized after your death. Establish Ownership Structures for Royalties Royalties can continue to generate income long after a musician’s passing. To ensure proper management, it is most efficient to set up a trust to collect and distribute these royalties to your beneficiaries. A trust can provide the mechanism to provide ongoing support to your loved ones to ensure they receive the funds in a way that makes sense, particularly if your beneficiaries are minors. Having a trust in place can also make it easier to manage the various income streams to ensure they flow centrally during your life in the way that you intend. Certain trusts can even provide creditor protection, protection from estate disputes, and mismanagement if you become incapacitated. When a trust is created, it is important to think about who will serve as your trustee if you can no longer act, or upon your death. The trustee chosen by you should have familiarity with your intellectual property, royalties, licensing, and the value of your catalogue. Assign Control Over Your Artistic Legacy Do you want your unreleased recordings shared with the world? Should certain songs be licensed for commercials or films? It is essential that you appoint the right person with this level of discretion to answer these questions because they can determine how your music is used after your death. It is, therefore, vital to ensure that the person you assign the control has an understanding of your legacy. This person is often referred to as a “creative executor” or a “creative trustee” who understands your artistic vision and can carry out your wishes regarding issues like posthumous releases, licensing decisions, and the preservation of your work. Digital Assets and Social Media A musician’s online presence can be as valuable as their physical recordings. A properly drafted estate plan will include instructions regarding your social media profiles, your official website, your digital music platforms (Spotify, Apple Music, YouTube channels), and access to each of those platforms. You may direct whether these platforms should remain active as they were during your life, or if you would prefer that they remain active as a memorial or taken down altogether. Business Succession Planning for Bands or Labels If you own a record label, music publishing company, or are part of a band with business agreements, succession planning is critical. Ensure that your partnership agreements address what happens in the event of your death or incapacity and how ownership interests will be transferred or managed. Your operating agreements and shareholder agreements should be reflective of your wishes and must address your particular circumstance; failure to do so allows your state to determine how those interests can be transferred or managed. Plan for Personal Assets and Family Needs Beyond your musical career, you must ensure that you have a traditional estate plan in place that also addresses bequests to your family members and friends, guardianship of your children, and designations of health agents and powers of attorney. If your musical career is successful, you should consider the issue of estate tax and consult with an insurance professional for life insurance policies that could provide economic support for your family or liquidity to pay estate tax. If your music catalog has significant value, proactive estate tax planning is essential. Strategies might include gifting portions of your catalog during your lifetime, setting up irrevocable trusts to shield assets, and working with a valuation expert to determine accurate appraisals for estate tax purposes. Musicians, like most artists, often experience fluctuating incomes, so proper planning is crucial for providing long-term security to loved ones. Final Thoughts Proper planning is the ultimate backstage pass to your legacy. It empowers musicians to control not just the financial aspects of their legacy, but also the integrity and future of their creative works. Without a solid plan, disputes over rights, royalties, and artistic decisions can tarnish the legacy you have worked so hard to build.
August 5, 2025
Franchise Law
Understanding the FDD and Franchise Agreement Before You Invest
Franchise Agreements Are Binding and Often One-Sided Franchise Agreements are typically drafted by the franchisor and presented on a “take it or leave it” basis. These contracts often impose strict controls over how you operate your business — from approved vendors and marketing strategies to pricing, hours of operation, and technology platforms. They also frequently include provisions that: Limit your ability to exit the business without penalties Impose personal guarantees and long-term non-competes Allow the franchisor to raise fees or change system rules unilaterally Require extensive marketing spend and recurring royalty payments, regardless of profitability Once signed, these agreements are legally binding, and courts generally enforce them as written. That’s why it’s critical to understand every term, especially the financial and operational obligations that can continue even if your business underperforms. The FDD Reveals More Than You Think—If You Know Where to Look Federal law requires all franchisors to provide an FDD at least 14 days before you commit to purchasing a franchise. This document includes 23 mandatory items covering everything from fees and restrictions to litigation history and franchisee turnover. Key areas to focus on include: Item Seven (Estimated Initial Investment): Are the start-up costs realistic? Do they include real estate, equipment, training, and working capital Item 19 (Financial Performance Representations): Does the franchisor provide actual revenue or profit data? If not, you’ll need to speak directly with current and former franchisees to assess performance Item 20 (System Growth and Turnover): How many outlets have closed, transferred, or terminated in the past three years? A high rate of turnover may signal problems in the system Location, Location, Location: Real Estate Considerations Matter For brick-and-mortar franchises, securing the appropriate location is mission-critical. But many prospective franchisees underestimate just how complex and time-consuming the real estate process can be. Questions to ask include: Will the franchisor assist with site selection and lease negotiations Does your market have sufficient demand for the service you're offering Have you accounted for construction costs, permitting delays, or the need for tenant improvements Before signing a lease, make sure your site is approved by the franchisor, zoned appropriately, and competitively situated within your target market. Poor location decisions can be fatal, even with a strong brand behind you. Due Diligence Is Not Optional — It’s Essential Even if a franchise system seems successful from the outside, the only way to know whether it’s viable for you is through diligent research. This includes: Contacting five to seven current and former franchisees in similar markets to ask about actual revenue, marketing effectiveness, franchisor support, and break-even timelines Building a financial model that includes royalties, fees, payroll, rent, and realistic revenue assumptions Consulting experienced franchise counsel to identify red flags or possible negotiation points (such as non-compete terms, marketing obligations, or transfer fees) Understand the Fine Print: Non-Competes and Post-Termination Restrictions One of the most overlooked — but potentially harmful — aspects of franchise agreements is the restrictive covenants that survive after your business ends. Most franchise agreements include: In-term and post-term non-compete clauses that prevent you from operating a similar business for up to two years within a certain geographic radius Non-solicitation provisions that restrict contact with former clients, employees, or vendors Injunctive relief and fee-shifting clauses that give the franchisor significant enforcement rights if they believe you’ve violated these obligations These provisions can limit your ability to earn a living in your field if things don’t work out. You must understand exactly what you are agreeing to before committing to the franchise. Franchise Investment Is a Long-Term Commitment Most franchise agreements last between five and 10 years, and renewal isn’t guaranteed. Even if renewal is offered, it often requires signing a new agreement that may include higher fees or stricter obligations. If your situation changes, selling or transferring your franchise may trigger high administrative fees or require franchisor approval. Some agreements even prohibit termination unless certain financial benchmarks are met. No Guarantees of Success Finally, it’s important to remember — buying a franchise is not a guarantee of success. Many franchisors explicitly disclaim responsibility for your profitability, and even those that provide financial data often include broad disclaimers. You bear the operational risk, and in many cases, personal financial risk. Bottom Line: Don’t Buy Blind The decision to invest in a franchise should be driven by facts — not hope, hype, or brand appeal. Review the FDD and Franchise Agreement in full. Speak to other franchisees. Build your own financial model. And don’t move forward until you’ve consulted an attorney who specializes in franchise law. The costs of skipping this step — both financial and emotional — can be far greater than you think.
August 5, 2025
Mergers and Acquisitions
Deal Flow Thawing: Is the M&A Market Finally Finding Its Footing?
After a rocky past six months, there is cautious optimism that merger and acquisition (M&A) activity is beginning to unfreeze. For much of the past year, there have been mismatched expectations around valuations and limited access to capital that have caused activity to stall. According to a recent report by PwC Global, “lending rates have long been one of the two key factors influencing M&A activity, the other being valuations.” So, while buyers were eager and sellers were hopeful, the numbers rarely lined up. But things could now start to change. The Valuation Tug-of-War One of the biggest barriers to getting deals across the finish line has been price. Many sellers have been holding onto lofty valuations based on pre-2022 market highs that simply aren’t realistic today. Meanwhile, buyers, who have been dealing with tighter credit markets and greater scrutiny from lenders, have been laser-focused on the fundamentals. All of this has resulted in a frustrating standoff where deals collapse not due to a lack of interest, but because no one can agree on what the business is truly worth. In fact, earlier this year, Arrowpoint Advisory noted a 26% decline in deal volume in North America, due in large part to “valuation mismatches between buyers and sellers.” We're now seeing a slow realignment. Valuation expectations are coming back to earth, with PwC noting that in today’s uncertain environment, it is important to not overreach on valuations. Deal structures are also evolving to bridge the remaining gaps, with earnouts, seller financing, and rollover equity becoming more common. It is this kind of flexibility that is helping to get deals done. A Shift in Diligence Dynamics Another notable change has been the quality of earnings (QoE) process. Two years ago, it was often a buyer-driven analysis, completed after signing a letter of intent (LOI). Now, many sellers are proactively conducting QoE studies before going to market. It’s a smart move to arm themselves with clean, vetted financials that can help to accelerate buyer confidence and reduce the risk of retrading. But there is a catch. Even with a proactive QoE, once a deal goes under LOI, buyers are digging deeper than ever. Diligence is intense, and the time from LOI to closing can stretch longer than expected. KPMG’s 2025 Deal Market Study points to heightened diligence and risk assessment as top challenges for 52% of corporates and 42% of private equity sponsors in the current economic landscape. And 47% of corporates also pointed to prolonged deal closing timelines as an issue, highlighting the link between deeper diligence and slower transactions. So, by the time due diligence wraps, earnings may have shifted, or market conditions may have changed, sometimes to the point where the lender’s original terms no longer match the reality of the deal. The Capital Crunch is Real, But Not Fatal Banks are still lending, but there is an increased level of caution and a decreased appetite for risk. We’ve seen situations where buyers get a term sheet for, say, $8 million in debt financing, only to find that after diligence or revised financials, the deal no longer pencils out, or the loan size is cut. That kind of late-stage shift can derail even the most promising transaction. That’s why it’s more important than ever to stress-test the deal early. Build in buffers, anticipate lender concerns, and don’t underestimate the importance of aligning everyone (seller, buyer, and lender) on realistic numbers from the start. The M&A market may not be booming, but the ice is cracking as valuations find firmer footing, buyers adapt to longer timelines, and sellers are more prepared. If you're contemplating a transaction on either side, now is the time to get your house in order. Quality of earnings, capital access, transparency, and flexibility will be the make-or-break factors in the deals that get done in the second half of 2025.
August 4, 2025
